```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 13:05:46 ON 20 AUG 2009
FILE 'REGISTRY' ENTERED AT 13:05:46 ON 20 AUG 2009
COPYRIGHT (C) 2009 American Chemical Society (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       1.44     584.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -4.92

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       1.44     584.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -4.92

FILE 'REGISTRY' ENTERED AT 13:05:54 ON 20 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 AUG 2009  HIGHEST RN 1174705-31-7
DICTIONARY FILE UPDATES:  19 AUG 2009  HIGHEST RN 1174705-31-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10519113news1.str
```





```
chain nodes :
1  2  10  11  12  13  14  15  16  17  18  19  22  23  24
ring nodes :
3  4  5  6  7  8
chain bonds :
1-10  1-2  1-19  2-3  2-24  4-15  4-16  5-17  5-18  6-22  7-11  7-12  8-13  8-14
22-23
ring bonds :
3-4  3-8  4-5  5-6  6-7  7-8
exact/norm bonds :
1-2  1-19  2-3  2-24  3-4  3-8  4-5  5-6  6-7  6-22  7-8
exact bonds :
1-10  4-15  4-16  5-17  5-18  7-11  7-12  8-13  8-14  22-23
isolated ring systems :
containing 3 :


G1:O,S,NH

Match level :
1:CLASS  2:CLASS  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  10:CLASS
11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:Atom  22:CLASS  23:CLASS  24:CLASS
Generic attributes :
19:
Saturation              : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System     : Monocyclic

Element Count :
Node 19: Limited
    C,C5-6
    N,N0-1




L24     STRUCTURE UPLOADED

=> d l24
L24 HAS NO ANSWERS
L24             STR
```



G1 O,S,NH

Structure attributes must be viewed using STN Express query preparation.

=> s l24 sss sam
SAMPLE SEARCH INITIATED 13:06:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1114 TO ITERATE

100.0% PROCESSED 1114 ITERATIONS 42 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 20278 TO 24282
PROJECTED ANSWERS: 452 TO 1228

L25 42 SEA SSS SAM L24

=> d scan

L25 42 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Benzoic acid, 3-[[[4-hydroxy-4-(5-methyl-2-pyridinyl)-1-piperidinyl]carbonyl]amino]-, ethyl ester
MF C21 H25 N3 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L25 42 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1-Piperidinecarboxamide, 4-(cyclopentylmethyl)-N-(3,5-difluorophenyl)-4-hydroxy-
MF C18 H24 F2 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L25 42 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy-4-(3-methylphenyl)-
MF C21 H20 F6 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L25 42 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 1-Piperidinecarboxamide, 4-cyclohexyl-N-(3,5-dichlorophenyl)-4-hydroxy-
MF C18 H24 Cl2 N2 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L25 42 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN

IN 1-Piperidinecarboxamide, 4-(2-ethylbutyl)-4-hydroxy-N-[3-(2-methoxyphenoxy)phenyl]-
MF C25 H34 N2 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l24 sss full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 185.40 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 13:06:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 21962 TO ITERATE

100.0% PROCESSED 21962 ITERATIONS 605 ANSWERS
SEARCH TIME: 00.00.01

L26 605 SEA SSS FUL L24

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	186.36	770.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.92

FILE 'CAPLUS' ENTERED AT 13:06:54 ON 20 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Aug 2009 VOL 151 ISS 8
FILE LAST UPDATED: 19 Aug 2009 (20090819/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

```
=> s l26
L27         58 L26

=> d ibib abs hitstr 58

L27  ANSWER 58 OF 58  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         1978:597599  CAPLUS
DOCUMENT NUMBER:          89:197599
ORIGINAL REFERENCE NO.:   89:30723a,30726a
TITLE:                    Amide derivatives of 3,4,5-trimethoxybenzene
INVENTOR(S):              Joullie, Maurice; Maillard, Gabriel; Warolin,
                          Christian Jean Marie; Lakah, Lucien
PATENT ASSIGNEE(S):       METABIO, Fr.
SOURCE:                   Ger. Offen., 36 pp.
                          CODEN: GWXXBX
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ----------------     ----   --------    --------------------     --------
     DE 2801187            A1    19780720    DE 1978-2801187          19780112
PRIORITY APPLN. INFO.:                       GB 1977-16055        A   19770114
GI
```



I



II

AB Sixty-six title compds. I [NRR1 = (un)substituted alkyl- or alkenylamino, cycloalkylamino, aralkylamino, tetrahydrofurfurylamino, pyrrolidino, piperidino, homopiperidino, isoxazolidinyl, morpholino, thiamorpholino, piperazino, tetrahydroquinolyl- or -isoquinolyl, tetrahydrobenzoxazinyl,

tetrahydropyranylmethylamino; Z = O, NR2 (R2 = H, PhCH2, morpholinoethyl); Z1 = CO, CONH, CO2, SO2; m, n = 0, 1, 2], useful as tranquilizers, anticonvulsants, or sedative potentiators (data tabulated), were prepared by 9 methods. Thus, 2,6-dimethylmorpholine was added to a stirred solution of 3,4,5-(MeO)3C6H2NCO in ether and the mixture refluxed with stirring 7 h to give 79% carbamoylmorpholine II.

IT 68060-95-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 68060-95-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

=> d ibib abs hitstr 57

L27 ANSWER 57 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1995:858623 CAPLUS
DOCUMENT NUMBER: 123:256357
ORIGINAL REFERENCE NO.: 123:45843a,45846a
TITLE: Preparation of anthranilic acid amide derivative as cyclic guanosine monophosphate-phosphodiesterase inhibitors
INVENTOR(S): Ozaki, Fumihiro; Ishibashi, Keiji; Ikuta, Hironori; Ishihara, Hiroki; Souda, Shigeru
PATENT ASSIGNEE(S): Japan
SOURCE: PCT Int. Appl., 204 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9518097	A1	19950706	WO 1994-JP2262	19941227
W: AU, CA, CN, FI, HU, KR, NO, NZ, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2155662	A1	19950706	CA 1994-2155662	19941227
AU 9512824	A	19950717	AU 1995-12824	19941227
AU 694465	B2	19980723		
EP 686625	A1	19951213	EP 1995-903999	19941227
EP 686625	B1	19990526		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1118595	A	19960313	CN 1994-191311	19941227
JP 08188563	A	19960723	JP 1994-336920	19941227
JP 3837673	B2	20061025		
HU 74450	A2	19961230	HU 1995-2512	19941227
RU 2128644	C1	19990410	RU 1995-120194	19941227
AT 180468	T	19990615	AT 1995-903999	19941227

FI 9503968	A	19951019	FI 1995-3968		19950823
NO 9503305	A	19951025	NO 1995-3305		19950823
US 5716993	A	19980210	US 1995-507476		19950914
PRIORITY APPLN. INFO.:			JP 1993-347092	A	19931227
			JP 1994-299110	A	19941109
			WO 1994-JP2262	W	19941227

OTHER SOURCE(S): MARPAT 123:256357
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Anthranilamide derivs. [I; R1, R2, R3, R4 = H, halo, OH, (halo)alkyl, (halo)alkoxy, nitro, hydroxyalkyl, cyano, (CH2)pNR9R10, S(O)qR13, (un)protected CO2H, (un)substituted tetrazolyl, CONH2, pyrazolyl, or imidazolyl; or adjacent two substituents selected from R1 - R4 together with the C atoms bonded to them forms a ring; wherein R9, R10 = H, (halo)alkyl, arylalkyl, heteroarylalkyl, acyl, (un)protected CO2H; or NR9R10 forms a ring; p = 0, 1-6; R13 = H, (halo)alkyl; q = 0, 1-2; R5, R6 = H, halo, OH, cyano, (halo)alkyl, (halo)alkoxy; or R5 and R6 together with the C atoms bonded to them form cycloalkane, oxolane, 1,3-dioxolane, or 1,4-dioxane ring; W = N, CH; R7, R8 = H, (halo)alkyl; or R1 and R7 together with the C atoms bonded to them form a ring optionally containing other N, O, or S atom; A = H, (halo)alkyl, X(CH2)mZ; wherein X = CO, CS, CH2, SO2; Z = OH, (halo)alkoxy, cyano, halo, etc.; Y = O, S; n = 0, 1-6] or pharmacol. acceptable salts thereof are prepared These compds. are useful for the treatment of ischemic heart disease, angina pectoris, hypertension, pulmonary hypertension, heart failure, and asthma. Thus, 2-nitro-5-chlorobenzoic acid was refluxed with SOCl2 in benzene for 4 h and concentrated to give 2-nitro-5-chlorobenzoyl chloride which was amidated with piperonylamine in the presence of Et3N in THF to give a benzamide (II; R = NO2). This compound was reduced by Fe powder in a mixture of AcOH, H2O, and MeOH under gentle refluxing to give, after concentration and treatment with concentrated HCl in EtOH, N-piperonylanthranilamide derivative II. HCl (R = NH2). An anthranilamide derivative (III) showed IC50 of 0.4 nM against cyclic guanosine monophosphate-phosphodiesterase preparation from pig aorta.

IT 169044-75-1P 169044-76-2P 169044-78-4P
169044-79-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate for preparation of anthranilamide derivs. as cyclic guanosine monophosphate-phosphodiesterase inhibitors)

RN 169044-75-1 CAPLUS
CN Benzoic acid, 5-chloro-2-[[(4-hydroxy-1-piperidinyl)carbonyl]amino]-, (4-methoxyphenyl)methyl ester (CA INDEX NAME)



RN 169044-76-2 CAPLUS
CN Benzoic acid, 5-cyano-2-[[(4-hydroxy-1-piperidinyl)carbonyl]amino]-, (4-methoxyphenyl)methyl ester (CA INDEX NAME)



RN 169044-78-4 CAPLUS
CN Benzoic acid, 5-chloro-2-[[(4-hydroxy-1-piperidinyl)carbonyl]amino]- (CA INDEX NAME)



RN 169044-79-5 CAPLUS
CN Benzoic acid, 5-cyano-2-[[(4-hydroxy-1-piperidinyl)carbonyl]amino]- (CA INDEX NAME)



IT 169043-97-4P 169043-99-6P 169044-00-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of anthranilamide derivs. as cyclic guanosine monophosphate-phosphodiesterase inhibitors)
RN 169043-97-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[2-[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]-4-chlorophenyl]-4-hydroxy- (CA INDEX NAME)



RN 169043-99-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-chloro-2-[[[(3-chloro-4-methoxyphenyl)methyl]amino]carbonyl]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 169044-00-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[2-[[[(3-chloro-4-methoxyphenyl)methyl]amino]carbonyl]-4-cyanophenyl]-4-hydroxy- (CA INDEX NAME)





OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 56

L27 ANSWER 56 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:241537 CAPLUS
DOCUMENT NUMBER: 124:289561
ORIGINAL REFERENCE NO.: 124:53702h,53703a
TITLE: Preparation of thienopyrimidinones as cyclic GMP phosphodiesterase inhibitors
INVENTOR(S): Oota, Tomoki; Kawashima, Yutaka; Hatayama, Katsuo
PATENT ASSIGNEE(S): Taisho Pharma Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07330777	A	19951219	JP 1994-126555	19940608
PRIORITY APPLN. INFO.:			JP 1994-126555	19940608

OTHER SOURCE(S): MARPAT 124:289561
GI



I

AB The title compds. I [R1 = alkyl; n = 0 or 1; X = halo, cycloalkyl, etc.] are prepared I [X = morpholino; n = 0; R1 = ethyl] (preparation given) at 28 μg/Kg decreased blood pressure in rats by 15 mmHg.

IT 175595-30-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thienopyrimidinones as cyclic GMP phosphodiesterase inhibitors)

RN 175595-30-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4-propoxy-3-(3,4,6,7-tetrahydro-4-oxothieno[3,2-d]pyrimidin-2-yl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

=> d ibib abs hitstr 55\
'55\' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO

```
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):0
'0' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
CLASS ------- IPC, NCL, ECLA, FTERM
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
```

```
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
              SCAN must be entered on the same line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, CLASS

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
              structure diagram, plus NTE and SEQ fields
KWIC -------- Hit term plus 20 words on either side
OCC --------- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes.  For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> d ibib abs hitstr 55

L27  ANSWER 55 OF 58  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         1996:446568  CAPLUS
DOCUMENT NUMBER:          125:114672
ORIGINAL REFERENCE NO.:   125:21527a,21530a
TITLE:                    Preparation of quinazoline derivatives as cyclic GMP
                          phosphodiesterase inhibitors
INVENTOR(S):              Oota, Tomoki; Taguchi, Minoru; Kawashima, Yutaka;
                          Hatayama, Katsuo
PATENT ASSIGNEE(S):       Taisho Pharmaceutical Co., Ltd., Japan
SOURCE:                   Jpn. Kokai Tokkyo Koho, 13 pp.
                          CODEN: JKXXAF
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
```

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08104679	A	19960423	JP 1995-175879	19950712
JP 3702493	B2	20051005		

PRIORITY APPLN. INFO.: JP 1995-175879 A 19950712
JP 1994-190388 19940812

OTHER SOURCE(S): MARPAT 125:114672

GI



I



II

AB The title compds. I [R1 = H, Me, etc.; R2 = alkyl; n = 0 or 1; X = halo, etc.] are prepared The title compound II (NMR data given) in vitro showed IC50 of 2.9 nM against cyclic GMP phosphodiesterase.

IT 178937-86-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline derivs. as cyclic GMP phosphodiesterase inhibitors)

RN 178937-86-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[3-(3,4-dihydro-8-methyl-4-oxo-2-quinazolinyl)-4-ethoxyphenyl]-4-hydroxy- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

=> d ibib abs hitstr 54

L27 ANSWER 54 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:751800 CAPLUS
DOCUMENT NUMBER: 126:31225
ORIGINAL REFERENCE NO.: 126:6353a,6356a
TITLE: Preparation of 1H-pyrazolo[3,4-d]pyrimidin-4-one derivatives as phosphodiesterase inhibitors
INVENTOR(S): Oota, Tomoki; Taguchi, Minoru; Kawashima, Yutaka; Hatayama, Katsuo; Tomizawa, Kazuyuki
PATENT ASSIGNEE(S): Taisho Pharma Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08253484	A	19961001	JP 1996-5930	19960117
JP 3713783	B2	20051109		
PRIORITY APPLN. INFO.:			JP 1995-6986 A	19950120

OTHER SOURCE(S): MARPAT 126:31225
GI



I

AB Title compds. I [R1 = C1-4 alkyl; X = phenoxy, NR2R3; R2, R3 = H, C2-4 hydroxyalkyl, or NR2R3 = morpholino, piperidino, etc.], phosphodiesterase inhibitors and therefore useful for treatment of hypertension and other cardiovascular diseases, (no data), are prepared Thus, I [R1 = Pr, X = PhO] was prepared from 6-(5-amino-2-propoxyphenyl)-4,5-dihydro-1,3-dimethyl-1H-pyrazolo[3,4-d]pyrimidin-4-one (preparation given) and Ph chloroformate. This was further reacted with morpholine to give I [R1 = Pr, X = morpholino]. In an in vitro study, this had an IC50 of 2.4 μM against phosphodiesterase.

IT 184356-81-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1H-pyrazolo[d]pyrimidinone derivs. as phosphodiesterase inhibitors)

RN 184356-81-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(4,5-dihydro-1,3-dimethyl-4-oxo-1H-pyrazolo[3,4-d]pyrimidin-6-yl)-4-ethoxyphenyl]-4-hydroxy- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

=> d ibib abs hitstr 53

L27 ANSWER 53 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1998:87720 CAPLUS
DOCUMENT NUMBER: 128:154098
ORIGINAL REFERENCE NO.: 128:30372h,30373a
TITLE: Preparation of certain substituted benzylamine derivatives such as amides of cis-1-(3-aminophenyl)-1-(4-phenyl-1-piperazinyl)-4-methylcyclohexane as a new class of neuropeptide Y1 specific ligands
INVENTOR(S): Blum, Charles A.; Hutchison, Alan; Peterson, John M.
PATENT ASSIGNEE(S): Neurogen Corp., USA
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9803493	A1	19980129	WO 1997-US12616		19970718
W: CA, JP, MX					
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
CA 2260982	A1	19980129	CA 1997-2260982		19970718
EP 915860	A1	19990519	EP 1997-934218		19970718
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
JP 2000515151	T	20001114	JP 1998-507103		19970718
MX 9900868	A	20000331	MX 1999-868		19990122
PRIORITY APPLN. INFO.:			US 1996-22329P	P	19960723
			WO 1997-US12616	W	19970718

OTHER SOURCE(S): MARPAT 128:154098
GI



I



II



III

AB The title compds. [I; one of X1, X2 and X3 = II and the remaining X1, X2 and X3 = H; W = H, C1-6 alkyl; Y = C, N, O, S; when Y = C then ZZ1 = N(OH), O, O(CH2)mO (wherein m = 2-3) or Z1 = H and Z = H, OH, NH2, etc.; when Y = N then Z = H, C1-6 alkyl and Z1 does not exist; Ar = (un)substituted Ph, pyridyl, thienyl, pyrimidyl; B = S, O, N(R5), C(R5)(R6); n = 1-3; R1, R2 = H, C1-6 alkyl; R3, R4 = H, C1-6 alkyl, C1-6 alkoxy; R5 = H, C1-6 alkyl, Ph, etc.; R6 = H, OH, NH2, etc.], useful in the diagnosis and treatment of feeding disorders such as obesity and bulimia and cardiovascular diseases such as essential hypertension and congestive heart failure due to the binding of these compds. to human neuropeptide Y1 receptors, were prepared Thus, treatment of cis-1-(3-aminophenyl)-1-(4-phenyl-1-piperazinyl)-4-methylcyclohexane (preparation described) with phosgene in the presence of Et3N in CH2Cl2 followed by addition of 1,4-dioxa-8-azaspiro[4.5]decane afforded the title compound cis-III. Compds. I are effective at 0.1-140 mg/kg/day.

IT 202472-22-8P 202472-28-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of certain substituted benzylamine derivs. such as amides of cis-1-(3-aminophenyl)-1-(4-phenyl-1-piperazinyl)-4-methylcyclohexane as a new class of neuropeptide Y1 specific ligands)

RN 202472-22-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[3-[cis-4-methyl-1-(4-phenyl-1-piperazinyl)cyclohexyl]phenyl]- (CA INDEX NAME)

Relative stereochemistry.



RN 202472-28-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[3-[cis-4-methyl-1-(4-phenyl-1-piperazinyl)cyclohexyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Relative stereochemistry.



● HCl

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 52

L27 ANSWER 52 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:126872 CAPLUS
DOCUMENT NUMBER: 130:196506
TITLE: Derivatives of 2,5- and 3,5-disubstituted anilines, their preparation, and use as potassium channel openers
INVENTOR(S): Dorwald, Florencio Zaragoza; Hansen, John Bondo; Mogensen, John Patrick; Tagmose, Tina Moller; Pirotte, Bernard; Lebrun, Philippe; De Tullio, Pascal; Boverie,

Stephane; Delarge, Jacques
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9907672	A1	19990218	WO 1998-DK337	19980724
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9885341	A	19990301	AU 1998-85341	19980724
EP 1019367	A1	20000719	EP 1998-936271	19980724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2003524574	T	20030819	JP 2000-507208	19980724
IN 1998MA01741	A	20050304	IN 1998-MA1741	19980804
ZA 9807026	A	20000207	ZA 1998-7026	19980805

PRIORITY APPLN. INFO.:	DK 1997-906	A	19970805
	US 1997-55193P	P	19970811
	WO 1998-DK337	W	19980724

OTHER SOURCE(S): MARPAT 130:196506
GI



AB Substituted anilines I [R1, R2 = H, CF3, halo, provided that both R1 and R2 ≠ H; R3 = CF3 or halo; R4 = (un)substituted alkyl or YR5; Y = O or NR6; R5, R6 = (un)substituted alkyl; or R5 and R6 form a 3- to 8-membered ring; X = O or S], their compns., and methods for preparing them are described. I are useful for the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the urogenital system, the gastrointestinal system and the endocrinol. system. In particular, the compds. are claimed as potassium channel openers useful in the treatment of endocrinol. diseases such as diabetes. Approx. 220 compds. are listed and claimed, and synthetic examples for several are provided. For instance, reaction of 2,4-dichlorobenzyl isocyanate with 3,5-bis(trifluoromethyl)aniline in PhMe at 90° in the presence of Et3N gave title compound II in 34% yield. The most active compds. showed IC50 values of 600 nM in an assay for potassium channel openers.

IT 220636-24-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of disubstituted aniline derivs. as potassium channel openers)
RN 220636-24-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 51

L27 ANSWER 51 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:733849 CAPLUS
DOCUMENT NUMBER: 131:337032
TITLE: Preparation of N-(1-phenylcycloalkyl)piperidines and analogs as neuropeptide Y1 receptor ligands
INVENTOR(S): Blum, Charles A.; Hutchison, Alan; Peterson, John M.
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: U.S., 11 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5985873	A	19991116	US 1997-897044	19970718
PRIORITY APPLN. INFO.:			US 1997-897044	19970718
OTHER SOURCE(S):	MARPAT 131:337032			

GI



I

AB Title compds. [I; R = Ph, pyridyl, thienyl, pyrimidinyl, etc.; R1,R2 = H or alkyl; R3,R4 = H, alkyl, alkoxy; 1 of X1-X3 = NR7COR8 and the others = H; R7 = H or alkyl; R8 = (thio)morpholino, (4-substituted) piperidino, (4-alkyl) piperazino; Z = O, NR5, CR5R6; R5 = alkyl, phenyl(alkyl), pyridyl(alkyl); R6 = H, NH2, alkyl, alkoxy, etc.; Z1 = (CH2)1-3] were

prepared as neuropeptide Y1 receptor ligands (no data). Thus, 4-methylcyclohexanone was condensed with 1-phenylpiperazine and KCN and the product condensed with 3-[(Me3Si)2N]C6H4MgCl to give, after deprotection, cis-I (R = Ph, R1-R4 = X1 = X3 = H, Z = CHMe, Z1 = CH2CH2)(II; X2 = NH2) which was condensed with COCl2 and 1,4-dioxa-8-azaspiro[4.5]decane to give, after hydrolysis, II (X2 = 4-oxopiperidinocarbonylamino).

IT 249732-72-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(1-phenylcycloalkyl)piperidines and analogs as neuropeptide Y1 receptor ligands)

RN 249732-72-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[3-[cis-4-methyl-1-(4-phenyl-1-piperazinyl)cyclohexyl]phenyl]-, hydrochloride (1:?) (CA INDEX NAME)

Relative stereochemistry.





●x HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 50

L27 ANSWER 50 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:260231 CAPLUS
DOCUMENT NUMBER: 132:293770
TITLE: Preparation of 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors
INVENTOR(S): Markwalder, Jay A.; Seitz, Steven P.; Sherk, Susan R.
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2000021926	A2	20000420	WO 1999-US23512	19991013
WO 2000021926	A3	20000803		
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6531477	B1	20030311	US 1999-416584	19991012
CA 2345809	A1	20000420	CA 1999-2345809	19991013
EP 1121363	A2	20010808	EP 1999-951875	19991013
EP 1121363	B1	20041222		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537223	T	20021105	JP 2000-575835	19991013
AT 285411	T	20050115	AT 1999-951875	19991013
ES 2235528	T3	20050701	ES 1999-951875	19991013
US 20020013328	A1	20020131	US 2001-794825	20010227
US 6559152	B2	20030506		
CA 2431038	A1	20020906	CA 2002-2431038	20020227
WO 2002067654	A2	20020906	WO 2002-US6002	20020227
WO 2002067654	A3	20021031		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002255614	A1	20020912	AU 2002-255614	20020227
EP 1383769	A2	20040128	EP 2002-725023	20020227
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004520407	T	20040708	JP 2002-567036	20020227

PRIORITY APPLN. INFO.:	US 1998-103957P	P	19981013
	US 1999-416584	A1	19991012
	WO 1999-US23512	W	19991013
	US 2001-794825	A	20010227
	WO 2002-US6002	W	20020227

OTHER SOURCE(S): MARPAT 132:293770

GI



I



II

AB The title compds. [I, alternatively represented by tautomer II; Q = H, OH,

Me, Et; Y = F, Cl, Br, I; Z = N, CR6; R1 = (un)substituted Ph, naphthyl, tropone, etc.; R2 = alkyl, alkenyl, alkynyl, etc.; R3 = H, F, Cl, etc.; R4 = H, F, Cl, etc.; R5 = H, alkyl, F, etc.; R6 = H, F, Cl, etc.] which are potent inhibitors of the class of enzymes known as cyclin dependent kinases (no data), which relate to the catalytic subunits cyclin dependent kinase 1-8 and their regulatory subunits known as cyclins A-H, K, N, and T, and are useful in treating cancer or other proliferative diseases, were prepared Thus, reacting 5-amino-3-methylthio-1-(2,4,6-trichlorophenyl)pyrazole-4-carboxamide with 3-methoxyphenylacetyl chloride in the presence of NaOEt in EtOH afforded 92% I [Q = H; Y = Cl; R1 = 3-MeOC6H4; R2 = MeS; R3, R4 = H; R5 = Cl; Z = CCl].

IT 264137-92-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors)

RN 264137-92-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[3-[[4,5-dihydro-3-(1-methylethyl)-4-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]methyl]phenyl]-4-hydroxy- (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 49

L27 ANSWER 49 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:420959 CAPLUS

DOCUMENT NUMBER: 133:43441

TITLE: Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

INVENTOR(S): Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III; Gardner, Daniel S.

PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 327 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2000035449	A1	20000622	WO 1999-US30292	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2346933	A1	20000622	CA 1999-2346933	19991217
EP 1156807	A1	20011128	EP 1999-968144	19991217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6331541	B1	20011218	US 1999-465288	19991217
TR 200101859	T2	20011221	TR 2001-1859	19991217
CN 1206219	C	20050615	CN 1999-814539	19991217
ZA 2001003756	A	20020509	ZA 2001-3756	20010509
US 20030013741	A1	20030116	US 2001-7172	20011023
US 6521592	B2	20030218		
US 20040002515	A1	20040101	US 2002-279416	20021024
US 6875776	B2	20050405		
US 20040006107	A1	20040108	US 2002-279231	20021024
US 6780857	B2	20040824		
US 20050096325	A1	20050505	US 2004-983367	20041108
US 20050192291	A1	20050901	US 2004-21042	20041223

PRIORITY APPLN. INFO.:

US 1998-112717P	P	19981218
US 1999-161221P	P	19991022
US 1999-161137P	P	19991022
US 1999-161184P	P	19991022
US 1999-161222P	P	19991022
US 1999-465287	A3	19991217
US 1999-465288	A3	19991217
US 1999-465948	A3	19991217
US 1999-466442	A3	19991217
WO 1999-US30292	W	19991217
US 2002-180869	A1	20020626
US 2002-279416	A1	20021024

OTHER SOURCE(S): MARPAT 133:43441

GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc,; Q = CH2, CHR5, etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may

join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage). [This abstract record is one of 9 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 275810-67-8P 275810-68-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)

RN 275810-67-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 275810-68-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 48

L27 ANSWER 48 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:420961 CAPLUS
DOCUMENT NUMBER: 133:43442
TITLE: Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
INVENTOR(S): Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III; Wacker, Dean A.; Watson, Paul S.; Varnes, Jeffrey G.
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 394 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035451	A1	20000622	WO 1999-US30332	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2350730	A1	20000622	CA 1999-2350730	19991217
EP 1140086	A1	20011010	EP 1999-964297	19991217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6331541	B1	20011218	US 1999-465288	19991217
ZA 2001003756	A	20020509	ZA 2001-3756	20010509
US 20030013741	A1	20030116	US 2001-7172	20011023
US 6521592	B2	20030218		
US 20040002515	A1	20040101	US 2002-279416	20021024
US 6875776	B2	20050405		
US 20040006107	A1	20040108	US 2002-279231	20021024
US 6780857	B2	20040824		
US 20050192291	A1	20050901	US 2004-21042	20041223

PRIORITY APPLN. INFO.:	US 1998-112717P	P	19981218
	US 1999-161243P	P	19991022
	US 1999-161137P	P	19991022
	US 1999-161184P	P	19991022
	US 1999-161222P	P	19991022
	US 1999-465287	A3	19991217
	US 1999-465288	A3	19991217
	US 1999-465948	A3	19991217
	WO 1999-US30332	W	19991217
	US 2002-279416	A1	20021024

OTHER SOURCE(S): MARPAT 133:43442
GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc,; Q = CH2, CH(CH2Ph), etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage). [This abstract record is one of 17 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 275810-67-8P 275810-68-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)

RN 275810-67-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 275810-68-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 47

L27 ANSWER 47 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:420962 CAPLUS
DOCUMENT NUMBER: 133:43443
TITLE: Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
INVENTOR(S): Ko, Soo S.; Delucca, George V.; Duncia, John V.; Kim, Ui Tae; Santella, Joseph B. Iii; Wacker, Dean A. K.
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 388 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035452	A1	20000622	WO 1999-US30334	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2347770	A1	20000622	CA 1999-2347770	19991217
EP 1161240	A1	20011212	EP 1999-963107	19991217
EP 1161240	B1	20050817		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6331541	B1	20011218	US 1999-465288	19991217
TR 200101859	T2	20011221	TR 2001-1859	19991217
BR 9917038	A	20020402	BR 1999-17038	19991217
JP 2002532427	T	20021002	JP 2000-587772	19991217
NZ 511394	A	20030725	NZ 1999-511394	19991217
AU 770042	B2	20040212	AU 2000-19406	19991217
CN 1206219	C	20050615	CN 1999-814539	19991217
AT 302005	T	20050915	AT 1999-963107	19991217
IN 2001MN00521	A	20050304	IN 2001-MN521	20010501
ZA 2001003756	A	20020509	ZA 2001-3756	20010509
NO 2001002977	A	20010820	NO 2001-2977	20010615
MX 2001006148	A	20010911	MX 2001-6148	20010615
US 20030013741	A1	20030116	US 2001-7172	20011023

US 6521592	B2	20030218			
US 20040002515	A1	20040101	US 2002-279416		20021024
US 6875776	B2	20050405			
US 20040006107	A1	20040108	US 2002-279231		20021024
US 6780857	B2	20040824			
US 20050096325	A1	20050505	US 2004-983367		20041108
US 20050192291	A1	20050901	US 2004-21042		20041223
PRIORITY APPLN. INFO.:			US 1998-112717P	P	19981218
			US 1999-161221P	P	19991022
			US 1999-161137P	P	19991022
			US 1999-161184P	P	19991022
			US 1999-161222P	P	19991022
			US 1999-465287	A3	19991217
			US 1999-465288	A3	19991217
			US 1999-465948	A3	19991217
			US 1999-466442	A3	19991217
			WO 1999-US30334	W	19991217
			US 2002-180869	A1	20020626
			US 2002-279416	A1	20021024

OTHER SOURCE(S): MARPAT 133:43443

GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc,; Q = CH2, CH(CH2Ph), etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage). [This abstract record is one of 9 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 275810-67-8P 275810-68-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)

RN 275810-67-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-

(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 275810-68-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 46

L27 ANSWER 46 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:420963 CAPLUS
DOCUMENT NUMBER: 133:43444
TITLE: Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
INVENTOR(S): Ko, Soo; Clark, Cheryl Mcardle; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III; Wacker, Dean A.
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Co., USA
SOURCE: PCT Int. Appl., 316 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2000035453	A1	20000622	WO 1999-US30335	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2347909	A1	20000622	CA 1999-2347909	19991217
EP 1158980	A1	20011205	EP 1999-965321	19991217
EP 1158980	B1	20050824		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6331541	B1	20011218	US 1999-465288	19991217
US 6486180	B1	20021126	US 1999-465948	19991217
AT 302606	T	20050915	AT 1999-965321	19991217
ZA 2001003756	A	20020509	ZA 2001-3756	20010509
US 20030013741	A1	20030116	US 2001-7172	20011023
US 6521592	B2	20030218		
US 20040002515	A1	20040101	US 2002-279416	20021024
US 6875776	B2	20050405		
US 20040006107	A1	20040108	US 2002-279231	20021024
US 6780857	B2	20040824		
US 20050192291	A1	20050901	US 2004-21042	20041223
PRIORITY APPLN. INFO.:			US 1998-112717P	P 19981218
			US 1999-161137P	P 19991022
			US 1999-161184P	P 19991022
			US 1999-161222P	P 19991022
			US 1999-465287	A3 19991217
			US 1999-465288	A3 19991217
			US 1999-465948	A3 19991217
			WO 1999-US30335	W 19991217
			US 2002-279416	A1 20021024

OTHER SOURCE(S): MARPAT 133:43444

GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc,; Q = CH2, CH(CH2Ph), etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/day (oral dosage).

[This abstract record is one of 9 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 275810-67-8P 275810-68-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)

RN 275810-67-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 275810-68-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 45

L27 ANSWER 45 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:420964 CAPLUS
DOCUMENT NUMBER: 133:43445
TITLE: Preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
INVENTOR(S): Ko, Soo S.; Duncia, John V. K.; Santella, Joseph B.,

III; Wacker, Dean A.; Kim, Ui Tae

PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA

SOURCE: PCT Int. Appl., 351 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035454	A1	20000622	WO 1999-US30336	19991217
W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2348923	A1	20000622	CA 1999-2348923	19991217
EP 1140087	A1	20011010	EP 1999-965322	19991217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6331541	B1	20011218	US 1999-465288	19991217
US 6492400	B1	20021210	US 1999-465287	19991217
ZA 2001003756	A	20020509	ZA 2001-3756	20010509
US 20030013741	A1	20030116	US 2001-7172	20011023
US 6521592	B2	20030218		
US 20040002515	A1	20040101	US 2002-279416	20021024
US 6875776	B2	20050405		
US 20040006107	A1	20040108	US 2002-279231	20021024
US 6780857	B2	20040824		
US 20050192291	A1	20050901	US 2004-21042	20041223

PRIORITY APPLN. INFO.:

US 1998-112717P	P	19981218
US 1999-161184P	P	19991022
US 1999-161137P	P	19991022
US 1999-161222P	P	19991022
US 1999-465287	A3	19991217
US 1999-465288	A3	19991217
US 1999-465948	A3	19991217
WO 1999-US30336	W	19991217
US 2002-279416	A1	20021024

OTHER SOURCE(S): MARPAT 133:43445

GI



I



II

AB The title compds. [I; M = absent, CH2, CH(CH2Ph), etc,; Q = CH2, CHR5, etc.; J, K, L = CH2, CH(CH2Ph), etc.; Z = O, S; E = (CH2)2, (CH2)3, CH2CH(OH)CH(Ph), etc.; R1, R2 = H, alkyl, alkenyl, etc.; R2 and R3 may join to form (un)substituted 5-7 membered ring; R3 = (un)substituted Ph, naphthyl, adamantyl, etc.; R4 = absent, alkyl, alkenyl, etc.], modulators of CCR3 useful for the prevention of asthma and other allergic diseases, were prepared and formulated. E.g., a multi-step synthesis of II was given. Compds. I are effective at 1.0-20 mg/kg/da (oral dosage). [This abstract record is one of 17 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 275810-67-8P 275810-68-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-ureidoalkyl-piperidines as modulators of chemokine receptor activity)

RN 275810-67-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 275810-68-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d ibib abs hitstr 44

L27  ANSWER 44 OF 58  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2001:935574  CAPLUS
DOCUMENT NUMBER:          136:69738
TITLE:                    Preparation of ureidoalkylpiperidines as modulators of
                          chemokine CCR3 receptor activity.
INVENTOR(S):              Ko, Soo S.; Delucca, George V.; Duncia, John V.;
                          Santella, Joseph B.; Wacker, Dean A.; Yao, Wenqing
PATENT ASSIGNEE(S):       Dupont Pharmaceuticals Company, USA; Bristol-Myers
                          Squibb Pharmaceutical Co.
SOURCE:                   PCT Int. Appl., 446 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   9
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2001098269         A2    20011227    WO 2001-US19745          20010620
     WO 2001098269         A3    20030710
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
             ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
             KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
             IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
             GW, ML, MR, NE, SN, TD, TG
     US 6605623            B1    20030812    US 2000-598821           20000621
     CA 2413274            A1    20011227    CA 2001-2413274          20010620
     EP 1363881            A2    20031126    EP 2001-950358           20010620
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI, CY, TR
     JP 2004517803         T     20040617    JP 2002-504225           20010620
PRIORITY APPLN. INFO.:                       US 2000-213051P     P    20000621
                                             US 2000-598821      A    20000621
                                             US 1998-112717P     P    19981218
                                             US 1999-161243P     P    19991022
                                             US 1999-465286      B2   19991217
                                             WO 2001-US19745     W    20010620
OTHER SOURCE(S):          MARPAT 136:69738
GI
```



I

AB [Title compds. I; M = CH2, CHR5, CHR13, CR13R13, CR5R13; Q = CH2, CHR5, CHR13, CR13R13, CR5R13; J, L = CH2, CHR5, CHR6, CR6R6, CR5R6; Z = O, S; M = CH2, CHR5, CHR13, CR13R13, CR5R13; K = CHR5, CR5R6; Z = O, S; E = (CHR7)(CHR9)v(CR11R12); R1, R2 = H, alkyl, alkenyl, alkynyl, (substituted) alkylcycloalkyl; R2R3 = atoms to form a (substituted) 5-7 membered ring; R3, R5 = (substituted) (alkyl)cycloalkyl, (alkyl)heterocyclyl; R4 = null,

O, alkyl, alkenyl, alkynyl, etc.; R4 with R7, R9, or R11 = atoms to form a 5-7 membered ring; R7, R9 = H; R4R7, R4R9 = (substituted) spirocyclyl; R13 = alkyl, alkenyl, alkynyl, cycloalkyl, etc.; R11R12 = pyrrolidinyl, tetrahydrofuryl, piperidinyl, tetrahydropyranyl; v = 1, 2], were prepared as modulators of chemokine activity (no data). Thus, 4-benzyl-1-(3-aminopropyl)piperidine (preparation given) in THF was treated with 3-cyanophenyl isocyanate to give N-(3-cyanophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea. [This abstract record is one of 15 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 275810-67-8P 275810-68-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ureidoalkylpiperidines as modulators of chemokine CCR3 receptor activity)

RN 275810-67-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 275810-68-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d ibib abs hitstr 43

L27  ANSWER 43 OF 58  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2001:935575  CAPLUS
DOCUMENT NUMBER:          136:69739
TITLE:                    Preparation of piperidinoalkylureas as chemokine
                          receptor modulators
INVENTOR(S):              Ko, Soo S.; Delucca, George V.; Duncia, John V.; Kim,
                          Ui Tae; Wacker, Dean A.; Zheng, Changsheng
PATENT ASSIGNEE(S):       Dupont Pharmaceuticals Company, USA
SOURCE:                   PCT Int. Appl., 333 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   9
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2001098270         A2    20011227    WO 2001-US19752         20010620
     WO 2001098270         A3    20020530
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
             ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 6525069            B1    20030225    US 2000-597400          20000621
     CA 2413421            A1    20011227    CA 2001-2413421         20010620
     EP 1294690            A2    20030326    EP 2001-950360          20010620
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2004516238         T     20040603    JP 2002-504226          20010620
PRIORITY APPLN. INFO.:                       US 2000-213208P     P   20000621
                                             US 2000-597400      A   20000621
                                             US 1998-112717P     P   19981218
                                             US 1999-161221P     P   19991022
                                             US 1999-466442      A2  19991217
                                             WO 2001-US19752     W   20010620

OTHER SOURCE(S):          MARPAT 136:69739
AB   The title compds. were prepared as chemokine receptor modulators (no data).
     Thus, PhCH2Z(CH2)3NHR (Z = piperidine-4,1-diyl)(I; R = H)(preparation given)
     was amidated by 3-(NC)C6H4NCO to give I [R = CONHC6H4(CN)-3].  [This
     abstract record is one of 9 records for this document necessitated by the
     large number of index entries required to fully index the document and
     publication system constraints.]
IT   275810-67-8P     275810-68-9P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (preparation of piperidinoalkylureas as chemokine receptor modulators)
RN   275810-67-8  CAPLUS
CN   1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-
     (phenylmethyl)-1-piperidinyl]methyl]phenyl]-  (CA INDEX NAME)
```



RN 275810-68-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 31 THERE ARE 31 CAPLUS RECORDS THAT CITE THIS RECORD (31 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 42

L27 ANSWER 42 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:71877 CAPLUS
DOCUMENT NUMBER: 136:134783
TITLE: Preparation of piperazine(or piperidine)-1-carboxamides as CCR5 modulators
INVENTOR(S): Bondinell, William E.; Neeb, Michael J.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005819	A1	20020124	WO 2001-US22529	20010713

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 2001080599	A	20020130	AU 2001-80599	20010713
EP 1313477	A1	20030528	EP 2001-958995	20010713
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040038982	A1	20040226	US 2003-343880	20030205
PRIORITY APPLN. INFO.:			US 2000-218509P	P 20000715
			WO 2001-US22529	W 20010713

OTHER SOURCE(S): MARPAT 136:134783

GI



I



II

AB The title compds. [I; the basic N atom in moiety E may be optionally quaternized with alkyl or optionally present as the N-oxide; A = (un)substituted (hetero)aryl or (hetero)aryl fused to a saturated or partly unsatd. 5-7 membered ring; D = a bond, CO, SO2, etc.; E1G = NC(R26)2, NC(R26)2C(R26)2, CR27C(R26)2, C:CR26; R26 = H, alkyl; R27 = H, CN, NO2, etc.; R = H, alkyl, O; J = CO, SO2; L = NR30, O, C(R30)2; R30 = H, alkyl; E = 3-(2-diisopropylamino)ethoxy-4-methoxyphenyl, etc.] which are modulators, agonists or antagonists, of the CCR5 receptor, and therefore are useful in the treatment and prevention of disease states mediated by CCR5, including, but not limited to, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis, or idiopathic pulmonary fibrosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, and inflammatory bowel disease, were prepared Thus, treating 4-phenyl-1,2,3,6-tetrahydropyridine.HCl with triphosgene in the presence of Et3N in CH2C12 followed by addition of 3-(2-diisopropylamino)ethoxy-4-methoxyaniline afforded II. The compds. I showed CCR5 receptor modulator activity having IC50 values in the range of 0.0001-100 μM. Furthermore, since CD8+ T cells have been implicated in COPD, CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therapeutic in the treatment of COPD.

Also, since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor modulators may be useful in the treatment of HIV infection.

IT 391881-92-8P 391882-01-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazine(or piperidine)-1-carboxamides as CCR5 modulators)

RN 391881-92-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-[2-[bis(1-methylethyl)amino]ethoxy]-4-methoxyphenyl]-4-(4-chlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 391882-01-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[4-methoxy-3-[1-(1-methylethyl)-4-piperidinyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 41

L27 ANSWER 41 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:72044 CAPLUS
DOCUMENT NUMBER: 136:134675
TITLE: Preparation of heterocyclic amino alcohol beta-3 adrenergic receptor agonists
INVENTOR(S): Ashwell, Mark Anthony; Solvibile, William Ronald; Quagliato, Dominick Anthony; Molinari, Albert John
PATENT ASSIGNEE(S): American Home Products Corporation, USA
SOURCE: PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002006229	A2	20020124	WO 2001-US22327	20010716
WO 2002006229	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 20020028832	A1	20020307	US 2001-903841	20010712
US 6451814	B2	20020917		
US 20030018045	A1	20030123	US 2002-189312	20020702
US 6605618	B2	20030812		
PRIORITY APPLN. INFO.:			US 2000-218628P	P 20000717
			US 2001-903841	A1 20010712

AB This invention provides A-U-CH(OH)CH2NHCH2CH2VC6H4WZ-p (1; Z = (1-Y-X-substituted piperidin-4-yl)) or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes. β3-Adrenergic receptor EC50 and maximal response (IA; % activity compound/% activity isoproterenol) values are reported for .apprx.100 example compds., e.g. 0.032 μM and 1.04 for 4-[4-[2-[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propylamino]ethyl]phenylamino]piperidine-1-carboxylic acid 2,6-difluorobenzylamide. In 1, A is (a) a 5-6 membered heterocyclic ring having 1-4 heteroatoms selected from O, N, and S, substituted with (R1)m; (b) a Ph ring substituted with (R1)m; (c) a naphthyl ring substituted with (R1)m; or (d) a Ph fused heterocycle selected from (R1)m-substituted 1,3-dihydro-2-oxo-2H-benzimidazol-4-yl, 1,3-benzodioxol-5-yl, 1,2,3,4-tetrahydro-2-oxoquinolin-5-yl, 1,2,3,4-tetrahydro-1-naphthylideneamino. U is -OCH2- or a bond; V is O or a bond; W is O, S(O)a, NR2, NC(O)R2; X = SO2, C(O), -(CH2)b, a bond, Ar; Y is -NR3R4, Het, Ar, alkyl of 1-8 C atoms, O(CH2)dR5. R1 is alkyl of 1-8 C atoms, -OR6, halogen, cyano, cycloalkyl of 3-8 C atoms, trifluoromethyl, CO2R6, -NR6R7, -C(O)NR6R7, -NHC(O)R6, -NR6C(O)NR8R8, -NHSO2R8, -S(O)aR6, -NO2, -O(CH2)eCO2R7, -OC(O)NR6R7, -O(CH2)fOR6, or a 5-6 membered heterocyclic ring containing 1 to 4 heteroatoms selected from O, S, and N. R2 is H, alkyl of 1-8 C atoms, or arylalkyl having 1-8 C atoms in the alkyl moiety; R3 and R4 are each, independently, H, alkyl of 1-8 C atoms, cycloalkyl of 3-8 C atoms, arylalkyl having 1-8 C atoms in the alkyl group, -(CH2)gR9, -(CH2)hCOR9, -(CH2)jCR10R11(CH2)jR9, or -(CH2)kCONR12R13; or R3 and R4 may be taken together together with the N to which they are attached to form a 3-7 membered saturated heterocycle, which may optionally contain 1-2 addnl. heteroatoms selected from O and S, and said heterocycle may optionally be substituted with R14. R5 is H; alkyl of 1-8 C atoms optionally substituted by 1-3 substituents selected from hydroxy, halogen and aryl; cycloalkyl of 1-8 C atoms; Ar or Het; R6, R7, and R8 are each, independently, H, or alkyl of 1-8 C atoms, or aryl of 6-10 C atoms, cycloalkyl of 3-8 C atoms, or arylalkyl having 1-8 C atoms in the alkyl moiety; R9 is H; alkyl optionally substituted with 1-3 substituents selected from hydroxy, halogen, and aryl; cycloalkyl of 3-8 C atoms; Ar, or Het; R10 and R11 are each, independently, H, alkyl, or aryl optionally substituted with alkyl of 1-8 C atoms or halogen; or R10 and R11 are taken together to form a spiro fused cycloalkyl ring of 3-8 C atoms. R12 and R13 are each, independently, H, alkyl of 1-8 C atoms, aryl optionally substituted with alkyl of 1-8 C atoms or halogen; or R12 and

R13 are taken together with the N to which they are attached to form a 3-7 membered saturated heterocycle, which may optionally contain 1-2 addnl. heteroatoms selected from O and S, and said heterocycle may optionally be substituted with R14; R14 is CO2R15 or aryl optionally substituted with a 1-3 substituents selected from -OR15 and cycloalkyloxy of 3-8 C atoms; R15 is alkyl of 1-8 C atoms or arylalkyl having 1-8 C atoms in the alkyl moiety. Ar is an aromatic ring system containing 1-2 carbocyclic aromatic rings having 6-10 C atoms optionally mono, di, or trisubstituted with R16; Het is (a) a 5-6 membered heterocyclic ring having 1-4 heteroatoms selected from O, S, and N which may be optionally mono- or disubstituted with R16; or (b) a heterocyclic ring system optionally mono- or disubstituted by R16 containing a 5-6 membered heterocyclic ring fused to one or two carbocyclic or heterocyclic rings such that the heterocyclic ring system contains 1-4 heteroatoms selected from O, S, and N; R16 is aryl, halogen, alkyl of 1-8 C atoms, -OR17, cycloalkyl of 3-8 C atoms, trifluoromethyl, cyano, -CO2R17, -CONR17R18, -SO2NR17R18, -NR17OR18, -NR19CONR1 7R18, -NR17R18, -NR17COR18, -NO2, -O(CH2)pCO2R17, -OCONR17R18, -S(O)nR17, -O(CH2)qOR17, or a 5-6 membered heterocyclic ring containing 1-4 heteroatoms selected from O, S and N. R17, R18, and R19 are each, independently, H, alkyl of 1-8 C atoms, arylalkyl having 1-8 C atoms in the alkyl moiety, or aryl optionally mono, di, or trisubstituted with halogen, cyano, nitro, hydroxy, alkyl of 1-8 C atoms, or alkoxy of 1-8 C atoms; or when R17 and R18 are contained on a common N, R17 and R18 may be taken together with the N to which they are attached to form a 3-7 membered saturated heterocycle, which may optionally contain 1-2 addnl. heteroatoms selected from O and S. A = 0-2; b = 1-6; d = 0-3; e = 1-6; f = 1-6; g = 0-6; h = 0-6; j = 0-6; k = 0-6; m = 0-2; p = 1-6; q = 1-6. Methods of preparation are claimed, comprising (a) reacting AOCH2-substituted oxirane or a protected form thereof in which a reactive substituent group is protected, with H2NCH2CH2VC6H4WZ-p or a protected form thereof in which a reactive substituent group is protected; and if required removing any protecting group to give 1 (U = -OCH2-). (b) reacting A-substituted oxirane or a protected form thereof in which any reactive substituent group is protected, with H2NCH2CH2VC6H4WZ-p or a protected form thereof in which a reactive substituent group is protected; and if required removing any protecting group to give 1 wherein U represents a bond;. (c) reacting ACH(OPr)CH2I, wherein Pr is a protecting group, with H2NCH2CH2VC6H4WZ-p or a protected form thereof in which a reactive substituent group is protected; and if required removing any protecting group to give 1 wherein U = -OCH2-. (d) reacting ACH(OH)CH2NH2 or a protected form thereof in which any reactive substituent group is protected, with HO2CCH2VC6H4WZ-p or a protected form thereof in which a reactive substituent group is protected; and if required removing any protecting group to give 1 wherein U = -OCH2-. (e) removing any protecting group from 1 in which at least one substituent carries a protecting group to give 1; or (f) converting a basic compound 1 to a salt thereof by reaction with a pharmaceutically acceptable acid; or (g) converting 1 having one or more reactive substituent groups to a different 1; or (h) isolating an isomer of 1 from a mixture thereof. More than 100 example prepns. are included.

IT 392628-39-6P, 4-Hydroxy-N-phenyl-1-piperidinecarboxamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of heterocyclic amino alc. beta-3 adrenergic receptor agonists)

RN 392628-39-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-phenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 40

L27 ANSWER 40 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:695940 CAPLUS
DOCUMENT NUMBER: 137:216688
TITLE: Preparation of substituted sulfonylalkylcarboxamides as selective pde3b inhibitors and use of the same in therapy
INVENTOR(S): Snyder, Peter B.; Beaton, Graham; Rueter, Jaimie K.; Fanning, Dewey L.; Warren, Stephen D.; Hadida-Ruah, Sara S.
PATENT ASSIGNEE(S): Icos Corporation, USA
SOURCE: PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002070469	A2	20020912	WO 2002-US5624		20020226
WO 2002070469	A3	20040304			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002247208	A1	20020919	AU 2002-247208		20020226
PRIORITY APPLN. INFO.:			US 2001-273497P	P	20010305
			WO 2002-US5624	W	20020226

OTHER SOURCE(S): MARPAT 137:216688
GI

I



II

AB Title compds. I [A = (un)substituted aryl or heteroaryl; B = (un)substituted aryl or heteroaryl which may optionally be a fused bicyclic or polycyclic aromatic ring system; Y = CHR4, CH2CHR4, CHR4CH2, NRc, CO(CH2)1-2S(CH2)0-2, O(CH2)0-4, NRcCO(CH2)0-2, and SO2NHRa(CH2)0-2; X = H, OH, alkoxy, cycloalkyl, CH(Rc)CH2OH, NRaRb, bond between NR2 and an atom of ring A or B, etc.; R0 = halo, alkyl, alkenyl, haloalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.; R1 = alkyl or halo; R2 = H, alkyl, aryl, heteroaryl, alkylenearyl, etc.; alternatively R2 and X may together form an (un)substituted heterocycle; R3 and R4 independently = H, alkyl, aryl, heteroaryl, halo; Ra and Rb independently = H, alkyl, aryl, arylalkyl, etc.; or Ra and Rb together form a (un)substituted 5-6 membered ring optionally containing a heteroatom; Rc = H, aryl, heteroaryl, alkyl, cycloalkyl, etc.], and their pharmaceutically acceptable salts and solvates thereof, are prepared and disclosed as selective PDE3B inhibitors. Thus, II was prepared via Suzuki coupling of 3,4,5-trimethoxyboronic acid with 4-bromophenylmethanesulfonyl-N-hydroxyethyl acetamide. In vitro assays against phosphodiesterase 3b indicated compds. of the invention possess IC50 values in the range of 0.01-8.5 μM.

IT 1106059-69-1
RL: PRPH (Prophetic)
(Preparation of substituted sulfonylalkylcarboxamides as selective pde3b inhibitors and use of the same in therapy)

RN 1106059-69-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-hydroxy-N-[4'-[[[2-[(2-hydroxyethyl)amino]-2-oxoethyl]sulfonyl]methyl][1,1'-biphenyl]-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d ibib abs hitstr 39

L27  ANSWER 39 OF 58  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2003:150534  CAPLUS
DOCUMENT NUMBER:          138:204946
TITLE:                    Preparation of N-ureidoalkylpiperidines as modulators
                          of CCR3 chemokine receptor activity for the prevention
                          of asthma and other allergic diseases
INVENTOR(S):              Ko, Soo S.; Delucca, George V.; Duncia, John V.; Kim,
                          Ui Tae; Wacker, Dean A.; Zheng, Changsheng
PATENT ASSIGNEE(S):       Bristol-Myers Squibb Pharma Company, USA
SOURCE:                   U.S., 126 pp., Cont.-in-part of U.S. Ser. No. 466,442.
                          CODEN: USXXAM
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   9
PATENT INFORMATION:

     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     ----------------      ----   --------    --------------------     --------
     US 6525069             B1    20030225    US 2000-597400           20000621
     US 6331541             B1    20011218    US 1999-465288           19991217
     US 6444686             B1    20020903    US 1999-466442           19991217
     ZA 2001003756          A     20020509    ZA 2001-3756             20010509
     CA 2413421             A1    20011227    CA 2001-2413421          20010620
     WO 2001098270          A2    20011227    WO 2001-US19752          20010620
     WO 2001098270          A3    20020530
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
             ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     EP 1294690             A2    20030326    EP 2001-950360           20010620
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2004516238          T     20040603    JP 2002-504226           20010620
     US 20030013741         A1    20030116    US 2001-7172             20011023
     US 6521592             B2    20030218
     US 20030114489         A1    20030619    US 2002-180869           20020626
     US 6897234             B2    20050524
     US 20040002515         A1    20040101    US 2002-279416           20021024
     US 6875776             B2    20050405
     US 20040006107         A1    20040108    US 2002-279231           20021024
     US 6780857             B2    20040824
     US 20040034063         A1    20040219    US 2003-359443           20030206
     US 6919368             B2    20050719
     US 20050096325         A1    20050505    US 2004-983367           20041108
     US 20050192291         A1    20050901    US 2004-21042            20041223
PRIORITY APPLN. INFO.:                         US 1998-112717P     P    19981218
                                               US 1999-161221P     P    19991022
                                               US 1999-466442      A2   19991217
                                               US 1999-161137P     P    19991022
                                               US 1999-161184P     P    19991022
                                               US 1999-161222P     P    19991022
                                               US 1999-465287      A3   19991217
                                               US 1999-465288      A3   19991217
                                               US 1999-465948      A3   19991217
```

US 2000-213208P	P	20000621
US 2000-597400	A	20000621
WO 2001-US19752	W	20010620
US 2002-180869	A1	20020626
US 2002-279416	A1	20021024

OTHER SOURCE(S): MARPAT 138:204946

GI



I

AB Title compds. [I; M, Q = CH2, CHR5, CHR13, CR13R13, CR5R13; J, K, L = CH2, CHR5, CHR6, CR6R6, CR5R6; ≥1 of J, K, L contains R5; Z = O, S, NR1a, CHCN, CHNO2, C(CN)2; R1a = H, alkyl, cycloalkyl, CN, NO2, etc.; E = (substituted) C3-6 carbocyclyl, methylenecarbocyclyl, ethylenecarbocyclyl, etc.; R1, R2 = H, alkyl, alkenyl, alkynyl; R3 = (substituted) alkyl, alkenyl, alkynyl; R4 = null, N-oxide, alkyl, alkenyl, alkynyl, cycloalkylalkyl, etc.; R5 = (substituted) alkylenecarbocyclyl, alkyleneheterocyclyl; R6 = alkyl, alkenyl, alkynyl, alkylcycloalkyl, perfluoroalkyl, hydroxyalkyl, mercaptoalkyl, aminoalkyl, CN, etc.; R13 = alkyl, alkenyl, alkynyl, cycloalkyl, perfluoroalkyl, aminoalkyl, hydroxyalkyl, carboxyalkyl, mercaptoalkyl, acylaminoalkyl, (substituted) phenylalkyl, etc.], were prepared as CCR3 modulators (no data). Thus, 4-benzyl-1-(3-aminopropyl)piperidine (preparation given) and 3-cyanophenyl isocyanate were stirred 30 min. in THF to give N-3-cyanophenyl-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea. [This abstract record is one of 8 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 275810-67-8P 275810-68-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-ureidoalkylpiperidines as modulators of chemokine receptor activity)

RN 275810-67-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 275810-68-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 38

L27 ANSWER 38 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:282524 CAPLUS
DOCUMENT NUMBER: 138:304064
TITLE: Preparation of phenylurea derivatives as vanilloid receptor agonists
INVENTOR(S): Matsumoto, Takahiro; Yamamoto, Masataka; Nagabukuro, Hiroshi; Mochizuki, Manabu
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 293 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003029199	A1	20030410	WO 2002-JP9995	20020927
WO 2003029199	A9	20030925		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002332331	A1	20030414	AU 2002-332331	20020927
EP 1437344	A1	20040714	EP 2002-768103	20020927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2004339061	A	20041202	JP 2002-282514	20020927
US 20040259912	A1	20041223	US 2004-489621	20040312
PRIORITY APPLN. INFO.:			JP 2001-300564	A 20010928
			WO 2002-JP9995	W 20020927

OTHER SOURCE(S): MARPAT 138:304064

GI



I

AB The title compds. I [R1, R4 and R6 are each independently hydrogen, halogeno, or hydrocarbyl; R2 is hydrocarbyl or a heterocyclic group; R3 is hydrocarbyl, etc.; R5 is hydrocarbyl or a heterocyclic group (except quinolyl) and R51 is hydrogen or hydrocarbyl, or R5 and R51 together with the nitrogen atom adjacent thereto may form a ring; and R52 is hydrogen or hydrocarbyl] are prepared I are useful for the treatment of pain, urinary incontinence, etc. In a tail flick test using mice, one compound of this invention showed a min. ED of 1 mg/kg.

IT 508216-23-7P 508216-25-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenylurea derivs. as vanilloid receptor agonists)

RN 508216-23-7 CAPLUS

CN Benzoic acid, 2-(diphenylmethoxy)-5-[[(4-hydroxy-1-piperidinyl)carbonyl]amino]-, methyl ester (CA INDEX NAME)



RN 508216-25-9 CAPLUS
CN Benzoic acid, 5-[[[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]carbonyl]amino]-2-(diphenylmethoxy)-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 37

L27 ANSWER 37 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:622568 CAPLUS
DOCUMENT NUMBER: 139:164710
TITLE: Preparation of ureidoalkylpiperidines as modulators of chemokine CCR3 receptor activity.
INVENTOR(S): Ko, Soo S.; Delucca, George V.; Duncia, John V.; Santella, Joseph B., III; Wacker, Dean A.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Pharma Company, USA
SOURCE: U.S., 145 pp., Cont.-in-part of U.S. Ser. No. 465,286, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6605623	B1	20030812	US 2000-598821	20000621
US 6331541	B1	20011218	US 1999-465288	19991217
ZA 2001003756	A	20020509	ZA 2001-3756	20010509
CA 2413274	A1	20011227	CA 2001-2413274	20010620
WO 2001098269	A2	20011227	WO 2001-US19745	20010620
WO 2001098269	A3	20030710		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1363881	A2	20031126	EP 2001-950358	20010620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
JP 2004517803	T	20040617	JP 2002-504225	20010620
US 20030013741	A1	20030116	US 2001-7172	20011023
US 6521592	B2	20030218		
US 20040002515	A1	20040101	US 2002-279416	20021024
US 6875776	B2	20050405		
US 20040006107	A1	20040108	US 2002-279231	20021024
US 6780857	B2	20040824		
US 20040058960	A1	20040325	US 2003-465191	20030619
US 6906066	B2	20050614		
US 20050192291	A1	20050901	US 2004-21042	20041223

PRIORITY APPLN. INFO.:

US 1998-112717P	P	19981218
US 1999-161243P	P	19991022
US 1999-465286	B2	19991217
US 1999-161137P	P	19991022
US 1999-161184P	P	19991022
US 1999-161222P	P	19991022
US 1999-465287	A3	19991217
US 1999-465288	A3	19991217
US 1999-465948	A3	19991217
US 2000-213051P	P	20000621
US 2000-598821	A	20000621
WO 2001-US19745	W	20010620
US 2002-279416	A1	20021024

OTHER SOURCE(S): MARPAT 139:164710

GI



I

AB [Title compds. I; M = CH2, CHR5, CHR13, CR13R13, CR5R13; Q = CH2, CHR5, CHR13, CR13R13, CR5R13; J, L = CH2, CHR5, CHR6, CR6R6, CR5R6; Z = O, S; M = CH2, CHR5, CHR13, CR13R13, CR5R13; K = CHR5, CR5R6; Z = O, S; E = (CHR7)(CHR9)v(CR11R12); R1, R2 = H, alkyl, alkenyl, alkynyl, (substituted) alkylcycloalkyl; R2R3 = atoms to form a (substituted) 5-7 membered ring; R3, R5 = (substituted) (alkyl)cycloalkyl, (alkyl)heterocyclyl; R4 = null, O, alkyl, alkenyl, alkynyl, etc.; R4 with R7, R9, or R11 = atoms to form a 5-7 membered ring; R6 = alkyl, alkenyl, alkynyl, etc.; R7, R9 = H; R4R7, R4R9 = (substituted) spirocyclyl; R13 = alkyl, alkenyl, alkynyl, cycloalkyl, etc.; R11R12 = pyrrolidinyl, tetrahydrofuryl, piperidinyl, tetrahydropyranyl; v = 1, 2], were prepared as modulators of chemokine activity (no data) for preventing asthma and other allergic diseases. Thus, 4-benzyl-1-(3-aminopropyl)piperidine (preparation given) in THF was treated with 3-cyanophenyl isocyanate to give

N-(3-cyanophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea. A pharmaceutical composition comprising the compound I was claimed. [This abstract record is one of 15 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 275810-67-8P 275810-68-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ureidoalkylpiperidines as modulators of chemokine CCR3 receptor activity)

RN 275810-67-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



RN 275810-68-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[2-[[4-(phenylmethyl)-1-piperidinyl]methyl]phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 25 THERE ARE 25 CAPLUS RECORDS THAT CITE THIS RECORD (27 CITINGS)
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 36

L27 ANSWER 36 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:892757 CAPLUS
DOCUMENT NUMBER: 139:381501

TITLE: Preparation of N-[thio(oxo)carbonylaminophenyl]uracils as herbicides

INVENTOR(S): Schwarz, Hans-Georg; Andree, Roland; Hoischen, Dorothee; Kluth, Joachim; Linker, Karl-Heinz; Vidal-Ferran, Anton; Drewes, Mark Wilhelm; Dahmen, Peter; Feucht, Dieter; Pontzen, Rolf

PATENT ASSIGNEE(S): Bayer CropScience AG, Germany

SOURCE: PCT Int. Appl., 118 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093244	A1	20031113	WO 2003-EP4138	20030422
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10219434	A1	20031120	DE 2002-10219434	20020502
CA 2484280	A1	20031113	CA 2003-2484280	20030422
AU 2003240459	A1	20031117	AU 2003-240459	20030422
AU 2003240459	B2	20081120		
EP 1503994	A1	20050209	EP 2003-729934	20030422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009872	A	20050419	BR 2003-9872	20030422
JP 2005535585	T	20051124	JP 2004-501383	20030422
MX 2004010863	A	20050214	MX 2004-10863	20041101
US 20060089262	A1	20060427	US 2005-514153	20051121
US 7521396	B2	20090421		

PRIORITY APPLN. INFO.:

DE 2002-10219434	A	20020502
WO 2003-EP4138	W	20030422

OTHER SOURCE(S): MARPAT 139:381501

GI



I

AB Title compds. [I; Q = O, S; R1 = H, amino, (substituted) alkyl; R2 = carboxy, cyano, (thio)carbamoyl, (substituted) alkyl, alkoxycarbonyl; R3 = H, halo, (halogenated) alkyl; R4 = H, cyano, (thio)carbamoyl, halo; R5 = cyano, (thio)carbamoyl, halo, (halogenated) alkyl, alkoxy; R6 = H, (substituted) alkyl, alkylcarbonyl, alkylsulfonyl, (halogenated) alkenyl, alkenylcarbonyl, etc.; R7 = (halogenated) alkoxycarbonyl,

alkoxycarbonylalkylthio, hydroxyamino, cyanoalkylamino, (substituted) heterocyclyloxy, N-bonded (monocyclic) N-heterocyclyl, etc.], were prepared Thus, a mixture of 3-(4-bromo-2-fluoro-5-isocyanatophenyl)-1-methyl-6-trifluoromethyl-1H-pyrimidin-2,4-one, piperidine-3-carboxylic acid Et ester, Et3N, and MeCN was stirred for 15 h at room temperature to give 42% 1-[2-bromo-4-fluoro-5-(3-methyl-2,6-dioxo-4-trifluoromethyl-3,6-dihydro-2H-pyrimidin-1-yl)phenylcarbamoyl]piperidine-3-carboxylic acid Et ester. I were said to show strong pre- and postemergent herbicidal activity and good crop tolerance.

IT 623929-28-2P 623929-29-3P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of [thio(oxo)carbonylaminophenyl]uracils as herbicides)

RN 623929-28-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1(2H)-pyrimidinyl]-4-fluorophenyl]-4-hydroxy- (CA INDEX NAME)



RN 623929-29-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[2-bromo-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1(2H)-pyrimidinyl]-4-fluorophenyl]-4-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 35

L27 ANSWER 35 OF 58 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:20537 CAPLUS
DOCUMENT NUMBER: 140:87699
TITLE: Remedies for diseases caused by vascular contraction or dilation
INVENTOR(S): Nakade, Shinji; Suzuki, Hidehiro; Habashita, Hiromu
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 216 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002531	A1	20040108	WO 2003-JP8039	20030625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003248245	A1	20040119	AU 2003-248245	20030625
EP 1522314	A1	20050413	EP 2003-761797	20030625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060148844	A1	20060706	US 2005-519113	20051101
PRIORITY APPLN. INFO.:			JP 2002-185546 A	20020626
			WO 2003-JP8039 W	20030625

OTHER SOURCE(S): MARPAT 140:87699

AB Remedies and/or preventives for diseases caused by vascular contraction or dilation which comprise EDG-5 regulators. EDG-5 regulators specifically bind to EDG-5 and show antagonism or agonism. Thus, an EDG-5 antagonist is useful in treating and/or preventing diseases caused by vascular contraction such as cerebrovascular spasmodic disease following subarachnoid hemorrhage or cerebral infarction, cardiovascular spasmodic disease, hypertension, kidney diseases, cardiac infarction, angina, arrhythmia, portal hypertension in association with cirrhosis and varicosity in association with cirrhosis. On the other hand, an EDG-5 agonist is useful in treating and/or preventing diseases caused by vascular dilation such as chronic headache (for example, hemicrania, tension headache, headache of the mixed type, cluster headache), hemorrhoid and cardiac diseases.

IT 401642-16-8P, N-(3-Chlorophenyl)-4-(4-chlorophenyl)-4-hydroxy-1-piperidinecarboxamide 401642-17-9P, 4-(4-Chlorophenyl)-N-(3,4-dichlorophenyl)-4-hydroxy-1-piperidinecarboxamide 642494-87-9P 642494-88-0P 642494-89-1P 642494-90-4P 642494-91-5P 642494-92-6P 642494-93-7P 642494-94-8P 642494-95-9P 642494-96-0P 642494-97-1P, 4-(4-Bromophenyl)-4-hydroxy-N-(3-((3-methylbutyl)amino)phenyl)-1-piperidinecarboxamide 642494-98-2P 642494-99-3P, N-(3-Cyanophenyl)-4-hydroxy-4-isopropyl-1-piperidinecarboxamide 642495-00-9P, N-(3-Fluorophenyl)-4-hydroxy-4-isopropyl-1-piperidinecarboxamide 642495-01-0P 642495-02-1P 642495-03-2P, 4-Cyclopentyl-N-(3,5-dichlorophenyl)-4-hydroxy-1-piperidinecarboxamide 642495-04-3P 642495-05-4P 642495-06-5P 642495-07-6P, N-(3,5-Bis(trifluoromethyl)phenyl)-4-(4-fluorophenyl)-4-hydroxy-1-piperidinecarboxamide 642495-09-8P, N-(3-Chlorophenyl)-4-cyclohexyl-4-hydroxy-1-piperidinecarboxamide 642495-10-1P 642495-11-2P, 4-Hydroxy-4-(3-methylbutyl)-N-(3-(trifluoromethyl)phenyl)-1-piperidinecarboxamide 642495-12-3P, N-(3,5-Bis(trifluoromethyl)phenyl)-4-hydroxy-4-(3-methylbutyl)-1-piperidinecarboxamide 642495-13-4P, N-(3,5-Dichlorophenyl)-4-hydroxy-4-(3-methylbutyl)-1-piperidinecarboxamide 642495-14-5P, 4-Cyclobutyl-4-hydroxy-N-(3-phenoxyphenyl)-1-piperidinecarboxamide 642495-15-6P, 4-Cyclobutyl-N-(3,5-dichlorophenyl)-4-hydroxy-1-piperidinecarboxamide 642495-16-7P 642495-17-8P 642495-18-9P, 4-(4-Bromophenyl)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-4-hydroxy-1-

piperidinecarboxamide 642495-19-0P,
4-Cyclobutyl-N-(3-fluoro-5-(trifluoromethyl)-phenyl)-4-hydroxy-1-
piperidinecarboxamide 642495-20-3P,
4-Cyclopentyl-N-(3-fluoro-5-(trifluoromethyl)-phenyl)-4-hydroxy-1-
piperidinecarboxamide 642495-21-4P 642495-22-5P
642495-23-6P 642495-24-7P 642495-25-8P,
N-(3-(Cyclohexyloxy)phenyl)-4-(2-ethylbutyl)-4-hydroxy-1-
piperidinecarboxamide 642495-26-9P,
4-(Cyclopentylmethyl)-4-hydroxy-N-(3-phenoxyphenyl)-1-
piperidinecarboxamide 642495-27-0P,
4-(Cyclopentylmethyl)-4-hydroxy-N-(3-(trifluoromethyl)phenyl)-1-
piperidinecarboxamide 642495-28-1P 642495-29-2P
642495-30-5P, 4-(1-Ethylpropyl)-4-hydroxy-N-(3-
(trifluoromethyl)phenyl)-1-piperidinecarboxamide 642495-31-6P
642495-32-7P, N-(3,5-Bis(trifluoromethyl)phenyl)-4-hydroxy-4-(3-
methylphenyl)-1-piperidinecarboxamide 642495-33-8P,
N-(3-Fluoro-5-(trifluoromethyl)phenyl)-4-hydroxy-4-(3-methylphenyl)-1-
piperidinecarboxamide 642495-34-9P,
N-(3,5-Bis(trifluoromethyl)phenyl)-4-hydroxy-4-(4-methylphenyl)-1-
piperidinecarboxamide 642495-35-0P,
N-(3-Fluoro-5-(trifluoromethyl)phenyl)-4-hydroxy-4-(4-methylphenyl)-1-
piperidinecarboxamide 642495-36-1P,
4-(4-Bromophenyl)-N-(3-chloro-5-fluorophenyl)-4-hydroxy-1-
piperidinecarboxamide 642495-37-2P,
N-(3-Chloro-5-fluorophenyl)-4-(4-chlorophenyl)-4-hydroxy-1-
piperidinecarboxamide 642495-38-3P,
N-(3-Chloro-5-fluorophenyl)-4-(4-fluorophenyl)-4-hydroxy-1-
piperidinecarboxamide 642495-39-4P 642495-40-7P
642495-41-8P 642495-42-9P 642495-43-0P
642495-44-1P 642495-45-2P,
N-(3,5-Bis(trifluoromethyl)phenyl)-4-butyl-4-hydroxy-1-
piperidinecarboxamide 642495-46-3P,
N-(3,5-Bis(trifluoromethyl)phenyl)-4-(4-bromophenyl)-4-hydroxy-1-
piperidinecarboxamide 642495-47-4P,
4-(2-Ethylbutyl)-4-hydroxy-N-(3-phenoxyphenyl)-1-piperidinecarboxamide
642495-48-5P 642495-49-6P,
N-(3,5-Bis(trifluoromethyl)phenyl)-4-(2-Ethylbutyl)-4-hydroxy-1-
piperidinecarboxamide 642495-50-9P 642495-51-0P
642495-52-1P 642495-53-2P 642495-54-3P
642495-55-4P 642495-56-5P,
4-Cyclohexyl-N-(3,5-Dichlorophenyl)-4-hydroxy-1-piperidinecarboxamide
642495-57-6P, N-(3,5-Bis(trifluoromethyl)phenyl)-4-
cyclopentylmethyl-4-hydroxy-1-piperidinecarboxamide 642495-58-7P
, N-(3,5-Bis(trifluoromethyl)phenyl)-4-(1-ethylpropyl)-4-hydroxy-1-
piperidinecarboxamide 642495-59-8P 642495-60-1P,
4-(1-Ethylpropyl)-4-hydroxy-N-(3-phenoxyphenyl)-1-piperidinecarboxamide
642495-61-2P 642495-62-3P,
N-(3,5-Bis(trifluoromethyl)phenyl)-4-cyclobutyl-4-hydroxy-1-
piperidinecarboxamide 642495-63-4P,
N-(3,5-Bis(trifluoromethyl)phenyl)-4-cyclopentyl-4-hydroxy-1-
piperidinecarboxamide 642495-64-5P,
N-(3,5-Bis(trifluoromethyl)phenyl)-4-hydroxy-4-(4-methoxyphenyl)-1-
piperidinecarboxamide 642495-65-6P,
N-(3,5-Bis(trifluoromethyl)phenyl)-4-hydroxy-4-(3-methoxyphenyl)-1-
piperidinecarboxamide 642495-66-7P 642495-67-8P
642495-68-9P 642495-69-0P 642495-70-3P
642495-71-4P 642495-72-5P 642495-74-7P
642495-75-8P 642495-76-9P 642495-77-0P
642495-78-1P 642495-79-2P,
N-(3,5-Dichlorophenyl)-4-hydroxy-4-(4-methylphenyl)-1-
piperidinecarboxamide 642495-80-5P 642495-81-6P
642495-82-7P 642495-83-8P 642495-84-9P

642495-85-0P 642495-86-1P 642495-87-2P
642495-88-3P 642495-89-4P 642495-90-7P,
4-Cyclopentyl-4-hydroxy-N-(3-(trifluoromethyl)phenyl)-1-
piperidinecarboxamide 642495-91-8P,
N-(3-Chlorophenyl)-4-cyclopentyl-4-hydroxy-1-piperidinecarboxamide
642495-92-9P, 4-Cyclopentyl-4-hydroxy-N-(3-ethylphenyl)-1-
piperidinecarboxamide 642495-93-0P 642495-94-1P,
4-Cyclopentyl-4-hydroxy-N-(3,4-dichlorophenyl)-1-piperidinecarboxamide
642495-95-2P 642495-96-3P,
4-Cyclohexyl-4-hydroxy-N-(2,6-dichloro-4-pyridyl)-1-piperidinecarboxamide
642495-97-4P, N-(2,6-Dichloro-4-pyridyl)-4-hydroxy-4-(3-
methylbutyl)-1-piperidinecarboxamide 642495-98-5P,
4-Cyclopropyl-4-hydroxy-N-(3-phenoxyphenyl)-1-piperidinecarboxamide
642495-99-6P, 4-Cyclopropyl-N-(3,5-dichlorophenyl)-4-hydroxy-1-
piperidinecarboxamide 642496-00-2P,
4-Cyclobutyl-4-hydroxy-N-(3-(trifluoromethyl)phenyl)-1-
piperidinecarboxamide 642496-01-3P,
N-(3,5-Dichlorophenyl)-4-hydroxy-4-(2-naphthyl)-1-piperidinecarboxamide
642496-02-4P 642496-04-6P 642496-05-7P
642496-06-8P 642496-07-9P 642496-08-0P
642496-09-1P, 4-tert-Butyl-N-(3-(Cyclohexyloxy)phenyl)-4-hydroxy-1-
piperidinecarboxamide 642496-10-4P,
4-Butyl-N-(3-(Cyclohexyloxy)phenyl)-4-hydroxy-1-piperidinecarboxamide
642496-11-5P, N-(3-(Cyclohexyloxy)phenyl)-4-hydroxy-4-(3-
methylbutyl)-1-piperidinecarboxamide 642496-12-6P,
N-(3-(Cyclohexyloxy)phenyl)-4-(cyclopentylmethyl)-4-hydroxy-1-
piperidinecarboxamide 642496-13-7P,
N-(3-Chlorophenyl)-4-(cyclopentylmethyl)-4-hydroxy-1-piperidinecarboxamide
642496-14-8P, 4-(Cyclopentylmethyl)-N-(2,6-dichloro-4-pyridyl)-4-
hydroxy-1-piperidinecarboxamide 642496-15-9P
642496-16-0P 642496-17-1P,
N-(3,5-Difluorophenyl)-4-hydroxy-4-(1-propylbutyl)-1-piperidinecarboxamide
642496-18-2P, N-(3-Chlorophenyl)-4-hydroxy-4-(1-propylbutyl)-1-
piperidinecarboxamide 642496-19-3P,
N-(3,5-Dichlorophenyl)-4-hydroxy-4-(1-propylbutyl)-1-piperidinecarboxamide
642496-20-6P, N-(2,6-Dichloro-4-pyridyl)-4-hydroxy-4-(1-
propylbutyl)-1-piperidinecarboxamide 642496-21-7P,
N-(3-(Cyclopentyloxy)phenyl)-4-(1-ethylpropyl)-4-hydroxy-1-
piperidinecarboxamide 642496-22-8P,
N-(3-(Cyclohexyloxy)phenyl)-4-(1-ethylpropyl)-4-hydroxy-1-
piperidinecarboxamide 642496-23-9P,
N-(3-Chlorophenyl)-4-(1-ethylpropyl)-4-hydroxy-1-piperidinecarboxamide
642496-24-0P, N-(2,6-Dichloro-4-pyridyl)-4-(1-ethylpropyl)-4-
hydroxy-1-piperidinecarboxamide 642496-25-1P,
N-(3,5-Bis(trifluoromethyl)phenyl)-4-hydroxy-4-(2-methylphenyl)-1-
piperidinecarboxamide 642496-26-2P,
N-(3-Fluoro-5-(trifluoromethyl)phenyl)-4-hydroxy-4-(2-methylphenyl)-1-
piperidinecarboxamide 642496-27-3P 642496-28-4P,
4-Benzyl-N-(3-Fluoro-5-(trifluoromethyl)phenyl)-4-hydroxy-1-
piperidinecarboxamide 642496-29-5P,
N-(3-Chloro-5-fluorophenyl)-4-hydroxy-4-phenyl-1-piperidinecarboxamide
642496-30-8P, N-(3-Chloro-5-fluorophenyl)-4-hydroxy-4-(4-
methylphenyl)-1-piperidinecarboxamide 642496-31-9P,
N-(3-Chloro-5-fluorophenyl)-4-hydroxy-4-(3-methylphenyl)-1-
piperidinecarboxamide 642496-32-0P,
N-(3-Chloro-5-fluorophenyl)-4-cyclobutyl-4-hydroxy-1-piperidinecarboxamide
642496-33-1P 642496-34-2P,
4-tert-Butyl-N-(3-Chloro-5-fluorophenyl)-4-hydroxy-1-piperidinecarboxamide
642496-35-3P, 4-Butyl-N-(3-Chloro-5-fluorophenyl)-4-hydroxy-1-
piperidinecarboxamide 642496-36-4P,
N-(3-Chloro-5-fluorophenyl)-4-hydroxy-4-(3-methylbutyl)-1-
piperidinecarboxamide 642496-37-5P,

N-(3-Chloro-5-fluorophenyl)-4-hydroxy-4-(1-propylbutyl)-1-piperidinecarboxamide 642496-38-6P 642496-39-7P 642496-40-0P, 4-Benzyl-N-(3-Chloro-5-fluorophenyl)-4-hydroxy-1-piperidinecarboxamide 642496-41-1P 642496-42-2P, 4-(4-Bromophenyl)-4-hydroxy-N-(3-(trifluoromethoxy)phenyl)-1-piperidinecarboxamide 642496-43-3P, 4-Hydroxy-4-isopropyl-N-(3-phenoxyphenyl)-1-piperidinecarboxamide 642496-44-4P, 4-(Cyclohexylmethyl)-4-hydroxy-N-(3-(trifluoromethyl)phenyl)-1-piperidinecarboxamide 642496-45-5P, 4-(Cyclohexylmethyl)-N-(3,5-dimethylphenyl)-4-hydroxy-1-piperidinecarboxamide 642496-46-6P, 4-(4-Bromophenyl)-4-hydroxy-N-(3-methylphenyl)-1-piperidinecarboxamide 642496-47-7P, 4-(4-Bromophenyl)-4-hydroxy-N-(4-(trifluoromethyl)phenyl)-1-piperidinecarboxamide 642496-48-8P, 4-(4-Bromophenyl)-N-(4-chlorophenyl)-4-hydroxy-1-piperidinecarboxamide 642496-49-9P 642496-50-2P, N,4-Bis(4-bromophenyl)-4-hydroxy-1-piperidinecarboxamide 642496-51-3P 642496-52-4P 642496-53-5P 642496-54-6P 642496-55-7P, Methyl 3-(((4-(4-bromophenyl)-4-hydroxy-1-piperidinyl)carbonyl)amino)benzoate 642496-56-8P, N-(3-Bromophenyl)-4-(4-bromophenyl)-4-hydroxy-1-piperidinecarboxamide 642496-57-9P 642496-58-0P 642496-59-1P 642496-60-4P 642496-61-5P 642496-62-6P 642496-63-7P, Methyl 3-(((4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)carbonyl)amino)benzoate 642496-64-8P, N-(3-Bromophenyl)-4-(4-chlorophenyl)-4-hydroxy-1-piperidinecarboxamide 642496-65-9P 642496-66-0P, Ethyl 3-(((4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)carbonyl)amino)benzoate 642496-67-1P 642496-68-2P 642496-69-3P 642496-70-6P 642496-71-7P 642496-72-8P, 4-(4-Chlorophenyl)-N-(2,6-dichlorophenyl)-4-hydroxy-1-piperidinecarboxamide 642496-73-9P, N-(3-Bromophenyl)-4-(4-fluorophenyl)-4-hydroxy-1-piperidinecarboxamide 642496-74-0P 642496-75-1P 642496-76-2P 642496-87-5P, N-(3-Bromophenyl)-4-hydroxy-4-phenyl-1-piperidinecarboxamide 642496-88-6P 642496-89-7P 642496-90-0P 642496-91-1P 642496-92-2P 642496-93-3P 642496-94-4P 642496-95-5P 642496-96-6P 642496-97-7P 642496-98-8P, N-(3,5-Dichlorophenyl)-4-hydroxy-4((6-methyl-3,4-dihydro-1(2H)-quinolinyl)methyl)-1-piperidinecarboxamide 642496-99-9P 642497-00-5P, 4-Butyl-N-(3-ethylphenyl)-4-hydroxy-1-piperidinecarboxamide 642497-01-6P 642497-02-7P 642497-03-8P 642497-04-9P 642497-05-0P 642497-06-1P 642497-07-2P 642497-08-3P 642497-09-4P 642497-10-7P 642497-11-8P 642497-12-9P 642497-13-0P 642497-14-1P 642497-15-2P 642497-16-3P, N-(3-Ethylphenyl)-4-hydroxy-4-pentyl-1-piperidinecarboxamide 642497-17-4P 642497-18-5P, Methyl 3-(((4-hexyl-4-hydroxy-1-piperidinyl)carbonyl)amino)benzoate 642497-19-6P 642497-20-9P 642497-21-0P 642497-22-1P 642497-23-2P 642497-24-3P 642497-25-4P 642497-26-5P 642497-27-6P 642497-28-7P 642497-29-8P 642497-30-1P 642497-31-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(EDG-5 agonists and antagonists as remedies for diseases caused by vascular contraction or dilation)

RN 401642-16-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chlorophenyl)-4-(4-chlorophenyl)-4-hydroxy-
(CA INDEX NAME)



RN 401642-17-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-N-(3,4-dichlorophenyl)-4-
hydroxy- (CA INDEX NAME)



RN 642494-87-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-(3,5-dichlorophenyl)-4-
hydroxy- (CA INDEX NAME)



RN 642494-88-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-(3-phenoxyphenyl)-
(CA INDEX NAME)



RN 642494-89-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-N-(3,5-dichlorophenyl)-4-
hydroxy- (CA INDEX NAME)



RN 642494-90-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-fluorophenyl)-4-hydroxy-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642494-91-5 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-(4-fluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642494-92-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-(3-phenoxyphenyl)-4-phenyl- (CA INDEX NAME)



RN 642494-93-7 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-hydroxy-4-phenyl- (CA INDEX NAME)



RN 642494-94-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2-ethylbutyl)-4-hydroxy-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642494-95-9 CAPLUS
CN 1-Piperidinecarboxamide, N-(2,6-dichloro-4-pyridinyl)-4-(2-ethylbutyl)-4-hydroxy- (CA INDEX NAME)



RN 642494-96-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[[(2E)-3-phenyl-2-propen-1-yl]amino]phenyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 642494-97-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[(3-methylbutyl)amino]phenyl]- (CA INDEX NAME)



RN 642494-98-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[[(2E)-3-(2-chlorophenyl)-2-propen-1-yl]amino]phenyl]-4-hydroxy- (CA INDEX NAME)

Double bond geometry as shown.



RN 642494-99-3 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-cyanophenyl)-4-hydroxy-4-(1-methylethyl)- (CA INDEX NAME)



RN 642495-00-9 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-fluorophenyl)-4-hydroxy-4-(1-methylethyl)- (CA INDEX NAME)



RN 642495-01-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(cyclohexylmethyl)-4-hydroxy-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642495-02-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopentyl-4-hydroxy-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642495-03-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopentyl-N-(3,5-dichlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-04-3 CAPLUS
CN Benzoic acid, 3-[[[4-hydroxy-4-(5-methyl-2-pyridinyl)-1-piperidinyl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 642495-05-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy-4-phenyl- (CA INDEX NAME)



RN 642495-06-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-(4-chlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-07-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-(4-fluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-09-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chlorophenyl)-4-cyclohexyl-4-hydroxy- (CA INDEX NAME)



RN 642495-10-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(3-methylbutyl)-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642495-11-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(3-methylbutyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642495-12-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy-4-(3-methylbutyl)- (CA INDEX NAME)



RN 642495-13-4 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-hydroxy-4-(3-methylbutyl)- (CA INDEX NAME)



RN 642495-14-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclobutyl-4-hydroxy-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642495-15-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclobutyl-N-(3,5-dichlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-16-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy-4-(2-naphthalenyl)- (CA INDEX NAME)



RN 642495-17-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy-4-phenyl- (CA INDEX NAME)



RN 642495-18-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642495-19-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclobutyl-N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642495-20-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopentyl-N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642495-21-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1,1-dimethylethyl)-N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642495-22-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-butyl-N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642495-23-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy-4-(3-methylbutyl)- (CA INDEX NAME)



RN 642495-24-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclohexyl-N-[3-(cyclohexyloxy)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642495-25-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(cyclohexyloxy)phenyl]-4-(2-ethylbutyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-26-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(cyclopentylmethyl)-4-hydroxy-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642495-27-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(cyclopentylmethyl)-4-hydroxy-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642495-28-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(cyclopentylmethyl)-N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642495-29-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(cyclopentylmethyl)-N-(3,5-difluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-30-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1-ethylpropyl)-4-hydroxy-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642495-31-6 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-(1-ethylpropyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-32-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy-4-(3-methylphenyl)- (CA INDEX NAME)



RN 642495-33-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy-4-(3-methylphenyl)- (CA INDEX NAME)



RN 642495-34-9 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy-4-(4-methylphenyl)- (CA INDEX NAME)



RN 642495-35-0 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy-4-(4-methylphenyl)- (CA INDEX NAME)



RN 642495-36-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-(3-chloro-5-fluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-37-2 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-(4-chlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-38-3 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-(4-fluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-39-4 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-cyclohexyl-4-hydroxy- (CA INDEX NAME)



RN 642495-40-7 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-(2-ethylbutyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-41-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-(1-ethylpropyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-42-9 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-(cyclopentylmethyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-43-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642495-44-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-butyl-N-(3,5-dichlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-45-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-butyl-4-hydroxy- (CA INDEX NAME)



RN 642495-46-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-(4-bromophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-47-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2-ethylbutyl)-4-hydroxy-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642495-48-5 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-(2-ethylbutyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-49-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-(2-ethylbutyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-50-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2-ethylbutyl)-N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642495-51-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-fluorophenyl)-N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642495-52-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642495-53-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclohexyl-4-hydroxy-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642495-54-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-cyclohexyl-4-hydroxy- (CA INDEX NAME)



RN 642495-55-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclohexyl-N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642495-56-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclohexyl-N-(3,5-dichlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-57-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-(cyclopentylmethyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-58-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-(1-ethylpropyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-59-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1-ethylpropyl)-N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642495-60-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1-ethylpropyl)-4-hydroxy-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642495-61-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-cyclopropyl-4-hydroxy- (CA INDEX NAME)



RN 642495-62-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-cyclobutyl-4-hydroxy- (CA INDEX NAME)



RN 642495-63-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-cyclopentyl-4-hydroxy- (CA INDEX NAME)



RN 642495-64-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy-4-(4-methoxyphenyl)- (CA INDEX NAME)



RN 642495-65-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy-4-(3-methoxyphenyl)- (CA INDEX NAME)



RN 642495-66-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2-ethylbutyl)-4-hydroxy-N-[3-[(tetrahydro-2H-pyran-2-yl)oxy]phenyl]- (CA INDEX NAME)



RN 642495-67-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2-ethylbutyl)-4-hydroxy-N-[3-(4-methylphenoxy)phenyl]- (CA INDEX NAME)



RN 642495-68-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2-ethylbutyl)-4-hydroxy-N-[3-(2-methylphenoxy)phenyl]- (CA INDEX NAME)



RN 642495-69-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2-ethylbutyl)-4-hydroxy-N-[3-(2-methoxyphenoxy)phenyl]- (CA INDEX NAME)



RN 642495-70-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2-ethylbutyl)-4-hydroxy-N-[3-(4-methoxyphenoxy)phenyl]- (CA INDEX NAME)



RN 642495-71-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2-ethylbutyl)-N-[3-(4-fluorophenoxy)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642495-72-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2-ethylbutyl)-4-hydroxy-N-[3-[4-(trifluoromethyl)phenoxy]phenyl]- (CA INDEX NAME)



RN 642495-74-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-(3-chlorophenyl)-4-hydroxy-
(CA INDEX NAME)



RN 642495-75-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-
(methylthio)phenyl]- (CA INDEX NAME)



RN 642495-76-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[3-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



RN 642495-77-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[3-
(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642495-78-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-fluorophenyl)-4-hydroxy-N-[3-
(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642495-79-2 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-hydroxy-4-(4-methylphenyl)- (CA INDEX NAME)



RN 642495-80-5 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-hydroxy-4-(3-thiazolidinylmethyl)- (CA INDEX NAME)



RN 642495-81-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-pentyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642495-82-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-hexyl-4-hydroxy-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642495-83-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,4-dichlorophenyl)-4-hydroxy-4-pentyl- (CA INDEX NAME)



RN 642495-84-9 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,4-dichlorophenyl)-4-hexyl-4-hydroxy- (CA INDEX NAME)



RN 642495-85-0 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[[ethyl[2-fluoro-3-(trifluoromethyl)benzoyl]amino]methyl]-4-hydroxy- (CA INDEX NAME)



RN 642495-86-1 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[(ethylthio)methyl]-4-hydroxy- (CA INDEX NAME)



RN 642495-87-2 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,4-dichlorophenyl)-4-[(ethylthio)methyl]-4-hydroxy- (CA INDEX NAME)



RN 642495-88-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1,1-dimethylethyl)-4-hydroxy-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642495-89-4 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-bromophenyl)-4-cyclopentyl-4-hydroxy- (CA INDEX NAME)



RN 642495-90-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopentyl-4-hydroxy-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642495-91-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chlorophenyl)-4-cyclopentyl-4-hydroxy- (CA INDEX NAME)



RN 642495-92-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopentyl-N-(3-ethylphenyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-93-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopentyl-N-(3,5-dimethylphenyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-94-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopentyl-N-(3,4-dichlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-95-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopentyl-N-(2,6-dichloro-4-pyridinyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-96-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclohexyl-N-(2,6-dichloro-4-pyridinyl)-4-hydroxy- (CA INDEX NAME)



RN 642495-97-4 CAPLUS
CN 1-Piperidinecarboxamide, N-(2,6-dichloro-4-pyridinyl)-4-hydroxy-4-(3-methylbutyl)- (CA INDEX NAME)



RN 642495-98-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-cyclopropyl-4-hydroxy-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642495-99-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopropyl-N-(3,5-dichlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-00-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclobutyl-4-hydroxy-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642496-01-3 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-hydroxy-4-(2-naphthalenyl)- (CA INDEX NAME)



RN 642496-02-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclohexyl-N-[3-(cyclopentyloxy)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642496-04-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(cyclopentyloxy)phenyl]-4-(2-ethylbutyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-05-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(cyclohexyloxy)phenyl]-4-hydroxy-4-phenyl- (CA INDEX NAME)



RN 642496-06-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(cyclohexyloxy)phenyl]-4-(4-fluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-07-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclobutyl-N-[3-(cyclohexyloxy)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642496-08-0 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(cyclohexyloxy)phenyl]-4-cyclopentyl-4-

hydroxy- (CA INDEX NAME)



RN 642496-09-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(cyclohexyloxy)phenyl]-4-(1,1-dimethylethyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-10-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-butyl-N-[3-(cyclohexyloxy)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642496-11-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(cyclohexyloxy)phenyl]-4-hydroxy-4-(3-methylbutyl)- (CA INDEX NAME)



RN 642496-12-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(cyclohexyloxy)phenyl]-4-(cyclopentylmethyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-13-7 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chlorophenyl)-4-(cyclopentylmethyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-14-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(cyclopentylmethyl)-N-(2,6-dichloro-4-pyridinyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-15-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-(3-phenoxyphenyl)-4-(1-propylbutyl)- (CA INDEX NAME)



RN 642496-16-0 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy-4-(1-propylbutyl)- (CA INDEX NAME)



RN 642496-17-1 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-difluorophenyl)-4-hydroxy-4-(1-propylbutyl)- (CA INDEX NAME)



RN 642496-18-2 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chlorophenyl)-4-hydroxy-4-(1-propylbutyl)-
(CA INDEX NAME)



RN 642496-19-3 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-hydroxy-4-(1-
propylbutyl)- (CA INDEX NAME)



RN 642496-20-6 CAPLUS
CN 1-Piperidinecarboxamide, N-(2,6-dichloro-4-pyridinyl)-4-hydroxy-4-(1-
propylbutyl)- (CA INDEX NAME)



RN 642496-21-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(cyclopentyloxy)phenyl]-4-(1-ethylpropyl)-4-
hydroxy- (CA INDEX NAME)



RN 642496-22-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(cyclohexyloxy)phenyl]-4-(1-ethylpropyl)-4-

hydroxy- (CA INDEX NAME)



RN 642496-23-9 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chlorophenyl)-4-(1-ethylpropyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-24-0 CAPLUS
CN 1-Piperidinecarboxamide, N-(2,6-dichloro-4-pyridinyl)-4-(1-ethylpropyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-25-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy-4-(2-methylphenyl)- (CA INDEX NAME)



RN 642496-26-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy-4-(2-methylphenyl)- (CA INDEX NAME)



RN 642496-27-3 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-cyclohexylphenyl)-4-hydroxy-4-(3-methylphenyl)- (CA INDEX NAME)



RN 642496-28-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy-4-(phenylmethyl)- (CA INDEX NAME)



RN 642496-29-5 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-hydroxy-4-phenyl- (CA INDEX NAME)



RN 642496-30-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-hydroxy-4-(4-methylphenyl)- (CA INDEX NAME)



RN 642496-31-9 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-hydroxy-4-(3-methylphenyl)- (CA INDEX NAME)



RN 642496-32-0 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-cyclobutyl-4-hydroxy- (CA INDEX NAME)



RN 642496-33-1 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-cyclopentyl-4-hydroxy- (CA INDEX NAME)



RN 642496-34-2 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-(1,1-dimethylethyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-35-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-butyl-N-(3-chloro-5-fluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-36-4 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-hydroxy-4-(3-methylbutyl)- (CA INDEX NAME)



RN 642496-37-5 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-hydroxy-4-(1-propylbutyl)- (CA INDEX NAME)



RN 642496-38-6 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-[(ethylthio)methyl]-4-hydroxy- (CA INDEX NAME)



RN 642496-39-7 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-hydroxy-4-(2-naphthalenyl)- (CA INDEX NAME)



RN 642496-40-0 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-hydroxy-4-(phenylmethyl)- (CA INDEX NAME)



RN 642496-41-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[(trifluoromethyl)thio]phenyl]- (CA INDEX NAME)



RN 642496-42-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 642496-43-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(1-methylethyl)-N-(3-phenoxyphenyl)-
(CA INDEX NAME)



RN 642496-44-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-(cyclohexylmethyl)-4-hydroxy-N-[3-
(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642496-45-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(cyclohexylmethyl)-N-(3,5-dimethylphenyl)-4-
hydroxy- (CA INDEX NAME)



RN 642496-46-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-(3-methylphenyl)-
(CA INDEX NAME)



RN 642496-47-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642496-48-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-(4-chlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-49-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-(4-ethoxyphenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-50-2 CAPLUS
CN 1-Piperidinecarboxamide, N,4-bis(4-bromophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-51-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-phenyl- (CA INDEX NAME)



RN 642496-52-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-(4-methoxyphenyl)-
(CA INDEX NAME)



RN 642496-53-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-(2-chlorophenyl)-4-hydroxy-
(CA INDEX NAME)



RN 642496-54-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[4-
(methylthio)phenyl]- (CA INDEX NAME)



RN 642496-55-7 CAPLUS
CN Benzoic acid, 3-[[[4-(4-bromophenyl)-4-hydroxy-1-
piperidinyl]carbonyl]amino]-, methyl ester (CA INDEX NAME)



RN 642496-56-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-bromophenyl)-4-(4-bromophenyl)-4-hydroxy-
(CA INDEX NAME)



RN 642496-57-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-(3-cyanophenyl)-4-hydroxy-
(CA INDEX NAME)



RN 642496-58-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-(3-phenoxyphenyl)-
(CA INDEX NAME)



RN 642496-59-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-(4-phenoxyphenyl)-
(CA INDEX NAME)



RN 642496-60-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-(3,5-difluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-61-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-(3,5-dimethylphenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-62-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-(3,4-dichlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-63-7 CAPLUS
CN Benzoic acid, 3-[[[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]carbonyl]amino]-, methyl ester (CA INDEX NAME)



RN 642496-64-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-bromophenyl)-4-(4-chlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-65-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-N-(3-cyanophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-66-0 CAPLUS
CN Benzoic acid, 3-[[[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 642496-67-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-[3-(methylthio)phenyl]- (CA INDEX NAME)



RN 642496-68-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-4-hydroxy-N-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 642496-69-3 CAPLUS
CN 1-Piperidinecarboxamide, N,4-bis(4-chlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-70-6 CAPLUS
CN 1-Piperidinecarboxamide, N-(4-bromophenyl)-4-(4-chlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-71-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-N-(3,5-difluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-72-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-chlorophenyl)-N-(2,6-dichlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-73-9 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-bromophenyl)-4-(4-fluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-74-0 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-ethylphenyl)-4-(4-fluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-75-1 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,4-dichlorophenyl)-4-(4-fluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642496-76-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N,4-bis[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642496-87-5 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-bromophenyl)-4-hydroxy-4-phenyl- (CA INDEX NAME)



RN 642496-88-6 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-ethylphenyl)-4-hydroxy-4-phenyl- (CA INDEX NAME)



RN 642496-89-7 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,4-dichlorophenyl)-4-hydroxy-4-phenyl- (CA INDEX NAME)



RN 642496-90-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(2-methylphenyl)-N-(3-phenoxyphenyl)-

(CA INDEX NAME)



RN 642496-91-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(3-methylphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642496-92-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(3-methylphenyl)-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642496-93-3 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-hydroxy-4-(3-methylphenyl)- (CA INDEX NAME)



RN 642496-94-4 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,4-dichlorophenyl)-4-hydroxy-4-(3-methylphenyl)- (CA INDEX NAME)



RN 642496-95-5 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichloro-4-pyridinyl)-4-hydroxy-4-(3-methylphenyl)- (CA INDEX NAME)



RN 642496-96-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(4-methylphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642496-97-7 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichloro-4-pyridinyl)-4-hydroxy-4-(4-methylphenyl)- (CA INDEX NAME)



RN 642496-98-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[(3,4-dihydro-6-methyl-1(2H)-quinolinyl)methyl]-4-hydroxy- (CA INDEX NAME)



RN 642496-99-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[1-[[(3,5-dichlorophenyl)amino]carbonyl]-4-hydroxy-4-piperidinyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 642497-00-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-butyl-N-(3-ethylphenyl)-4-hydroxy- (CA INDEX NAME)



RN 642497-01-6 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-fluorophenyl)-4-hydroxy-4-methyl- (CA INDEX NAME)



RN 642497-02-7 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-fluorophenyl)-4-hydroxy-4-propyl- (CA INDEX NAME)



RN 642497-03-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-bromophenyl)-4-butyl-4-hydroxy- (CA INDEX NAME)



RN 642497-04-9 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-hydroxy-4-propyl- (CA INDEX NAME)



RN 642497-05-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-methyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642497-06-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-butyl-4-hydroxy-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642497-07-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-ethyl-4-hydroxy-N-[3-(methylthio)phenyl]- (CA INDEX NAME)



RN 642497-08-3 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chlorophenyl)-4-hydroxy-4-methyl- (CA INDEX NAME)



RN 642497-09-4 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,4-dichlorophenyl)-4-hydroxy-4-methyl- (CA INDEX NAME)



RN 642497-10-7 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chlorophenyl)-4-hydroxy-4-propyl- (CA INDEX NAME)



RN 642497-11-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,4-dichlorophenyl)-4-hydroxy-4-propyl- (CA INDEX NAME)



RN 642497-12-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-butyl-N-(3-chlorophenyl)-4-hydroxy- (CA INDEX

NAME)



RN 642497-13-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-butyl-N-(3,4-dichlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642497-14-1 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichloro-4-pyridinyl)-4-hydroxy-4-propyl- (CA INDEX NAME)



RN 642497-15-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-butyl-N-(3,5-dichloro-4-pyridinyl)-4-hydroxy- (CA INDEX NAME)



RN 642497-16-3 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-ethylphenyl)-4-hydroxy-4-pentyl- (CA INDEX NAME)



RN 642497-17-4 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-fluorophenyl)-4-hydroxy-4-pentyl- (CA INDEX NAME)



RN 642497-18-5 CAPLUS
CN Benzoic acid, 3-[[(4-hexyl-4-hydroxy-1-piperidinyl)carbonyl]amino]-, methyl ester (CA INDEX NAME)



RN 642497-19-6 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-cyanophenyl)-4-hydroxy-4-pentyl- (CA INDEX NAME)



RN 642497-20-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-pentyl-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642497-21-0 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-cyanophenyl)-4-hexyl-4-hydroxy- (CA INDEX NAME)



RN 642497-22-1 CAPLUS
CN Benzoic acid, 3-[[(4-hydroxy-4-pentyl-1-piperidinyl)carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 642497-23-2 CAPLUS
CN Benzoic acid, 3-[[(4-hexyl-4-hydroxy-1-piperidinyl)carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 642497-24-3 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-difluorophenyl)-4-hydroxy-4-pentyl- (CA INDEX NAME)



RN 642497-25-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[3-(methylthio)phenyl]-4-pentyl- (CA INDEX NAME)



RN 642497-26-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-hexyl-4-hydroxy-N-[3-(methylthio)phenyl]- (CA INDEX NAME)



RN 642497-27-6 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chlorophenyl)-4-hydroxy-4-pentyl- (CA INDEX NAME)



RN 642497-28-7 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chlorophenyl)-4-hexyl-4-hydroxy- (CA INDEX NAME)



RN 642497-29-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichloro-4-pyridinyl)-4-hydroxy-4-pentyl- (CA INDEX NAME)



RN 642497-30-1 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[[ethyl(3-methylbenzoyl)amino]methyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-31-2 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[[ethyl(4-

methylbenzoyl)amino]methyl]-4-hydroxy- (CA INDEX NAME)



IT 642497-32-3P 642497-33-4P 642497-34-5P
642497-35-6P 642497-36-7P 642497-37-8P
642497-38-9P 642497-39-0P 642497-40-3P
642497-41-4P 642497-42-5P 642497-43-6P
642497-44-7P 642497-45-8P 642497-46-9P
642497-47-0P 642497-48-1P 642497-49-2P
642497-50-5P, 4-(4-Bromophenyl)-4-hydroxy-N-(3-((3-
methylbenzoyl)amino)phenyl)-1-piperidinecarboxamide 642497-51-6P
642497-52-7P, 4-(4-Bromophenyl)-4-hydroxy-N-(3-
(heptanoylamino)phenyl)-1-piperidinecarboxamide 642497-53-8P,
4-(4-Bromophenyl)-4-hydroxy-N-(3-((2-methoxybenzoyl)amino)phenyl)-1-
piperidinecarboxamide 642497-54-9P 642497-55-0P
642497-56-1P 642497-57-2P,
4-(4-Bromophenyl)-4-hydroxy-N-(3-((3-phenylpropanoyl)amino)phenyl)-1-
piperidinecarboxamide 642497-58-3P 642497-59-4P
642497-60-7P 642497-61-8P 642497-62-9P
642497-63-0P 642497-64-1P 642497-65-2P
642497-66-3P 642497-67-4P 642497-68-5P
642497-69-6P 642497-70-9P 642497-71-0P
642497-72-1P 642497-73-2P 642497-74-3P
642497-75-4P 642497-76-5P 642497-77-6P
642497-78-7P 642497-79-8P 642497-80-1P
642497-81-2P 642497-82-3P 642497-83-4P
642497-84-5P 642497-85-6P 642497-86-7P
642497-87-8P 642497-88-9P 642497-89-0P
642497-90-3P 642497-91-4P 642497-92-5P
642497-93-6P 642497-94-7P 642497-95-8P
642497-96-9P 642497-97-0P 642497-98-1P
642497-99-2P 642498-00-8P 642498-01-9P
642498-02-0P 642498-03-1P 642498-04-2P
642498-05-3P, Ethyl 3-(((4-tert-butyl-4-hydroxy-1-
piperidinyl)carbonyl)amino)benzoate 642498-06-4P
642498-07-5P 642498-08-6P 642498-09-7P
642498-10-0P 642498-11-1P 642498-12-2P
642498-13-3P 642498-14-4P 642498-15-5P
642498-16-6P 642498-17-7P 642498-18-8P
642498-19-9P 642498-20-2P 642498-21-3P
642498-22-4P 642498-23-5P 642498-24-6P
642498-25-7P, 4-Hydroxy-N-(3-methoxyphenyl)-4-(5-methyl-2-pyridyl)-
1-piperidinecarboxamide 642498-26-8P 642498-27-9P
642498-28-0P 642498-29-1P 642498-30-4P
642498-31-5P 642498-32-6P 642498-33-7P
642498-34-8P 642498-35-9P,
N-(3,5-Dichlorophenyl)-4-hydroxy-4-(1-piperidinecarbonyl)-1-
piperidinecarboxamide 642498-36-0P,
4-Benzyl-N-(3,5-bis(trifluoromethyl)phenyl)-4-hydroxy-1-
piperidinecarboxamide 642498-37-1P 642498-38-2P
642498-39-3P 642498-40-6P 642498-41-7P
642498-42-8P 642498-43-9P 642498-44-0P
642498-45-1P 642498-46-2P 642498-47-3P

642498-48-4P 642498-49-5P 642498-50-8P
642498-51-9P 642498-52-0P 642498-53-1P
642498-54-2P 642498-55-3P,
N-(3-(Cyclopentyloxy)phenyl)-4-hydroxy-4-phenyl-1-piperidinecarboxamide
642498-56-4P 642498-57-5P 642498-58-6P
642498-59-7P 642498-60-0P 642498-61-1P
642498-62-2P 642498-63-3P 642498-64-4P,
N-(3-(Cyclohexyloxy)phenyl)-4-hydroxy-4-(1-propylbutyl)-1-
piperidinecarboxamide 642498-65-5P 642498-66-6P
642498-67-7P 642498-68-8P 642498-69-9P
642498-70-2P, N-(3-Chloro-5-fluorophenyl)-4-hydroxy-4-(2-
methylphenyl)-1-piperidinecarboxamide 642498-71-3P
642498-72-4P 642498-73-5P 642498-75-7P
642498-76-8P 642498-77-9P,
N-(3,5-Dichlorophenyl)-4-(ethoxymethyl)-4-hydroxy-1-piperidinecarboxamide
642498-78-0P 642498-79-1P 642498-80-4P
642498-81-5P 642498-82-6P 642498-83-7P
642498-84-8P 642498-85-9P 642498-86-0P
642498-87-1P, Ethyl 3-(((4-(4-bromophenyl)-4-hydroxy-1-
piperidinyl)carbonyl)amino)benzoate 642498-88-2P
642498-89-3P 642498-90-6P 642498-91-7P
642498-92-8P 642498-93-9P 642498-94-0P,
4-Hydroxy-4-(5-methyl-2-pyridinyl)-N-(3-phenoxyphenyl)-1-
piperidinecarboxamide 642498-95-1P 642498-96-2P
642498-97-3P 642499-00-1P 642592-56-1P
642592-62-9P 642592-73-2P 642592-79-8P
642592-86-7P 642592-92-5P 642592-99-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(EDG-5 agonists and antagonists as remedies for diseases caused by
vascular contraction or dilation)

RN 642497-32-3 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[[ethyl(1-
oxoheptyl)amino]methyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-33-4 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[[ethyl(1-
oxohexyl)amino]methyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-34-5 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[[ethyl[(2E)-1-oxo-3-

phenyl-2-propen-1-yl]amino]methyl]-4-hydroxy- (CA INDEX NAME)

Double bond geometry as shown.



RN 642497-35-6 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[[ethyl(2-naphthalenylcarbonyl)amino]methyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-36-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[(3-chlorobenzoyl)ethylamino]methyl]-N-(3,5-dichlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642497-37-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[(2,3-dichlorobenzoyl)ethylamino]methyl]-N-(3,5-dichlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642497-38-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[(3-cyclopentyl-1-oxopropyl)ethylamino]methyl]-N-(3,5-dichlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642497-39-0 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[[(2,4-difluorobenzoyl)ethylamino]methyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-40-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[(2-cyclopentylacetyl)ethylamino]methyl]-N-(3,5-dichlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642497-41-4 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[[[2-(3,4-dimethoxyphenyl)acetyl]ethylamino]methyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-42-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[(3-chloro-4-fluorobenzoyl)ethylamino]methyl]-N-(3,5-dichlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642497-43-6 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[[ethyl[2-fluoro-5-(trifluoromethyl)benzoyl]amino]methyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-44-7 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[[ethyl[3-fluoro-4-(trifluoromethyl)benzoyl]amino]methyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-45-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[[ethyl[(2E)-1-oxo-3-[3-(trifluoromethyl)phenyl]-2-propen-1-yl]amino]methyl]-4-hydroxy- (CA INDEX NAME)

Double bond geometry as shown.



RN 642497-46-9 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[[ethyl(3-fluoro-4-methylbenzoyl)amino]methyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-47-0 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[[ethyl[4-(trifluoromethyl)benzoyl]amino]methyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-48-1 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[[ethyl[[(1R,2R)-2-phenylcyclopropyl]carbonyl]amino]methyl]-4-hydroxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 642497-49-2 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-[[ethyl[2-fluoro-4-(trifluoromethyl)benzoyl]amino]methyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-50-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[(3-methylbenzoyl)amino]phenyl]- (CA INDEX NAME)



RN 642497-51-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[(4-fluorobenzoyl)amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-52-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[(1-oxoheptyl)amino]phenyl]- (CA INDEX NAME)



RN 642497-53-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[(2-methoxybenzoyl)amino]phenyl]- (CA INDEX NAME)



RN 642497-54-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[(1-oxohexyl)amino]phenyl]- (CA INDEX NAME)



RN 642497-55-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[(2-chlorobenzoyl)amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-56-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[(1-oxooctyl)amino]phenyl]- (CA INDEX NAME)



RN 642497-57-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[(1-oxo-3-phenylpropyl)amino]phenyl]- (CA INDEX NAME)



RN 642497-58-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[(3-methoxybenzoyl)amino]phenyl]- (CA INDEX NAME)



RN 642497-59-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[(2-thienylcarbonyl)amino]phenyl]- (CA INDEX NAME)



RN 642497-60-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[[4-(trifluoromethyl)benzoyl]amino]phenyl]- (CA INDEX NAME)



RN 642497-61-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[(1-oxo-3-phenoxy-2-propyn-1-yl)amino]phenyl]- (CA INDEX NAME)



RN 642497-62-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[(3,4-dichlorobenzoyl)amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-63-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[(2,4-difluorobenzoyl)amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-64-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[(2,5-difluorobenzoyl)amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-65-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[(2-ethoxybenzoyl)amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-66-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[(4-cyanobenzoyl)amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-67-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[(3,5,5-trimethyl-1-oxohexyl)amino]phenyl]- (CA INDEX NAME)



RN 642497-68-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[(2-piperidinylcarbonyl)amino]phenyl]- (CA INDEX NAME)



RN 642497-69-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[(2,3-difluorobenzoyl)amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-70-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[(2,5-dimethoxybenzoyl)amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-71-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[(3,4-dimethoxybenzoyl)amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-72-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[(cyclobutylcarbonyl)amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-73-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[[2-fluoro-5-(trifluoromethyl)benzoyl]amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-74-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[[5-fluoro-2-(trifluoromethyl)benzoyl]amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-75-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[[3-fluoro-4-(trifluoromethyl)benzoyl]amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-76-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[(3,5-dimethoxybenzoyl)amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-77-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[[2-fluoro-3-(trifluoromethyl)benzoyl]amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-78-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[[4-fluoro-2-(trifluoromethyl)benzoyl]amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-79-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[[2-(difluoromethyl)benzoyl]amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-80-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[(2-chloro-5-fluorobenzoyl)amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-81-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-[[2-chloro-4-(trifluoromethyl)benzoyl]amino]phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-82-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[[2-(trifluoromethyl)benzoyl]amino]phenyl]- (CA INDEX NAME)



RN 642497-83-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-[(3,5-dichlorobenzoyl)amino]phenyl]-4-hydroxy-4-(1-methylethyl)- (CA INDEX NAME)



RN 642497-84-5 CAPLUS
CN Benzoic acid, 3-[[[4-(cyclohexylmethyl)-4-hydroxy-1-piperidinyl]carbonyl]amino]-, methyl ester (CA INDEX NAME)



RN 642497-85-6 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-bromophenyl)-4-(cyclohexylmethyl)-4-hydroxy-
(CA INDEX NAME)



RN 642497-86-7 CAPLUS
CN Benzoic acid, 3-[[[4-(cyclohexylmethyl)-4-hydroxy-1-
piperidinyl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 642497-87-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(cyclohexylmethyl)-4-hydroxy-N-[3-
(methylthio)phenyl]- (CA INDEX NAME)



RN 642497-88-9 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chlorophenyl)-4-(cyclohexylmethyl)-4-hydroxy-
(CA INDEX NAME)



RN 642497-89-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-(cyclohexylmethyl)-N-(3-ethylphenyl)-4-hydroxy- (CA INDEX NAME)



RN 642497-90-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-(cyclohexylmethyl)-4-hydroxy-N-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 642497-91-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-(cyclohexylmethyl)-N-(3,5-dichlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642497-92-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(cyclohexylmethyl)-N-(3,4-dichlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642497-93-6 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-bromophenyl)-4-[(ethylthio)methyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-94-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-[(ethylthio)methyl]-4-hydroxy-N-(3-methoxyphenyl)- (CA INDEX NAME)



RN 642497-95-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-[(ethylthio)methyl]-4-hydroxy-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642497-96-9 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chlorophenyl)-4-[(ethylthio)methyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-97-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-[(ethylthio)methyl]-4-hydroxy-N-(3-methylphenyl)- (CA INDEX NAME)



RN 642497-98-1 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-ethylphenyl)-4-[(ethylthio)methyl]-4-hydroxy- (CA INDEX NAME)



RN 642497-99-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-[(ethylthio)methyl]-N-(3-fluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642498-00-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-[(ethylthio)methyl]-4-hydroxy-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642498-01-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-[(ethylthio)methyl]-4-hydroxy-N-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 642498-02-0 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dimethylphenyl)-4-[(ethylthio)methyl]-4-hydroxy- (CA INDEX NAME)



RN 642498-03-1 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichloro-4-pyridinyl)-4-[(ethylthio)methyl]-4-hydroxy- (CA INDEX NAME)



RN 642498-04-2 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-bromophenyl)-4-(1,1-dimethylethyl)-4-hydroxy- (CA INDEX NAME)



RN 642498-05-3 CAPLUS
CN Benzoic acid, 3-[[[4-(1,1-dimethylethyl)-4-hydroxy-1-piperidinyl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 642498-06-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1,1-dimethylethyl)-4-hydroxy-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642498-07-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1,1-dimethylethyl)-4-hydroxy-N-[3-(methylthio)phenyl]- (CA INDEX NAME)



RN 642498-08-6 CAPLUS

CN 1-Piperidinecarboxamide, N-(3-chlorophenyl)-4-(1,1-dimethylethyl)-4-hydroxy- (CA INDEX NAME)



RN 642498-09-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1,1-dimethylethyl)-4-hydroxy-N-(3-methylphenyl)- (CA INDEX NAME)



RN 642498-10-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1,1-dimethylethyl)-N-(3-ethylphenyl)-4-hydroxy- (CA INDEX NAME)



RN 642498-11-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1,1-dimethylethyl)-4-hydroxy-N-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 642498-12-2 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-(1,1-dimethylethyl)-4-hydroxy- (CA INDEX NAME)



RN 642498-13-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-(1,1-dimethylethyl)-N-(3,5-dimethylphenyl)-4-hydroxy- (CA INDEX NAME)



RN 642498-14-4 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,4-dichlorophenyl)-4-(1,1-dimethylethyl)-4-hydroxy- (CA INDEX NAME)



RN 642498-15-5 CAPLUS
CN Benzoic acid, 3-[[(4-cyclopentyl-4-hydroxy-1-piperidinyl)carbonyl]amino]-, methyl ester (CA INDEX NAME)



RN 642498-16-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopentyl-4-hydroxy-N-(3-methylphenyl)- (CA INDEX NAME)



RN 642498-17-7 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-cyanophenyl)-4-cyclopentyl-4-hydroxy- (CA INDEX NAME)



RN 642498-18-8 CAPLUS
CN Benzoic acid, 3-[[(4-cyclopentyl-4-hydroxy-1-piperidinyl)carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 642498-19-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopentyl-4-hydroxy-N-[3-(methylthio)phenyl]- (CA INDEX NAME)



RN 642498-20-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopentyl-N-(3-fluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642498-21-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopentyl-4-hydroxy-N-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 642498-22-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopentyl-4-hydroxy-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642498-23-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopentyl-N-(3,5-difluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642498-24-6 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-bromophenyl)-4-hydroxy-4-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 642498-25-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-(3-methoxyphenyl)-4-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 642498-26-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-cyanophenyl)-4-hydroxy-4-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 642498-27-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(5-methyl-2-pyridinyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642498-28-0 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-ethylphenyl)-4-hydroxy-4-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 642498-29-1 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-fluorophenyl)-4-hydroxy-4-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 642498-30-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(5-methyl-2-pyridinyl)-N-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 642498-31-5 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dimethylphenyl)-4-hydroxy-4-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 642498-32-6 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,4-dichlorophenyl)-4-hydroxy-4-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 642498-33-7 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichloro-4-pyridinyl)-4-hydroxy-4-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 642498-34-8 CAPLUS
CN 1,4-Piperidinedicarboxamide, N1-(3,5-dichlorophenyl)-N4,N4-diethyl-4-hydroxy- (CA INDEX NAME)



RN 642498-35-9 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-hydroxy-4-(1-piperidinylcarbonyl)- (CA INDEX NAME)



RN 642498-36-0 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy-4-(phenylmethyl)- (CA INDEX NAME)



RN 642498-37-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642498-38-2 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-(1,1-dimethylethyl)-4-hydroxy- (CA INDEX NAME)



RN 642498-39-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-[(ethylthio)methyl]-4-hydroxy- (CA INDEX NAME)



RN 642498-40-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(phenylmethyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642498-41-7 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-hydroxy-4-(phenylmethyl)- (CA INDEX NAME)



RN 642498-42-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chlorophenyl)-4-hydroxy-4-(3-methylbutyl)- (CA INDEX NAME)



RN 642498-43-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-cyclopropyl-4-hydroxy-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642498-44-0 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chlorophenyl)-4-cyclobutyl-4-hydroxy- (CA INDEX NAME)



RN 642498-45-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclobutyl-4-hydroxy-N-(4-phenoxyphenyl)- (CA INDEX NAME)



RN 642498-46-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(2-naphthalenyl)-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642498-47-3 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chlorophenyl)-4-hydroxy-4-(2-naphthalenyl)- (CA INDEX NAME)



RN 642498-48-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(1-naphthalenyl)-N-(3-phenoxyphenyl)-
(CA INDEX NAME)



RN 642498-49-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(1-naphthalenyl)-N-[3-
(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642498-50-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-hydroxy-4-(1-
naphthalenyl)- (CA INDEX NAME)



RN 642498-51-9 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy-4-(4-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 642498-52-0 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy-4-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642498-53-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy-4-(2-naphthalenyl)- (CA INDEX NAME)



RN 642498-54-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-[(ethylthio)methyl]-N-[3-fluoro-5-(trifluoromethyl)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642498-55-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(cyclopentyloxy)phenyl]-4-hydroxy-4-phenyl- (CA INDEX NAME)



RN 642498-56-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-[3-(cyclopentyloxy)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642498-57-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(cyclopentyloxy)phenyl]-4-(4-fluorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642498-58-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclobutyl-N-[3-(cyclopentyloxy)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642498-59-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopentyl-N-[3-(cyclopentyloxy)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642498-60-0 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(cyclopentyloxy)phenyl]-4-(1,1-dimethylethyl)-4-hydroxy- (CA INDEX NAME)



RN 642498-61-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-butyl-N-[3-(cyclopentyloxy)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642498-62-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(cyclopentylmethyl)-N-[3-

(cyclopentyloxy)phenyl]-4-hydroxy- (CA INDEX NAME)



RN 642498-63-3 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(cyclopentyloxy)phenyl]-4-hydroxy-4-(1-propylbutyl)- (CA INDEX NAME)



RN 642498-64-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(cyclohexyloxy)phenyl]-4-hydroxy-4-(1-propylbutyl)- (CA INDEX NAME)



RN 642498-65-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(1-propylbutyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642498-66-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(cyclohexyloxy)phenyl]-4-hydroxy-4-(4-methylphenyl)- (CA INDEX NAME)



RN 642498-67-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[3-(cyclopentyloxy)phenyl]-4-hydroxy-4-(3-methylphenyl)- (CA INDEX NAME)



RN 642498-68-8 CAPLUS
CN 1-Piperidinecarboxamide, N-[3-(cyclopentyloxy)phenyl]-4-hydroxy-4-(4-methylphenyl)- (CA INDEX NAME)



RN 642498-69-9 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-hydroxy-4-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 642498-70-2 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-hydroxy-4-(2-methylphenyl)- (CA INDEX NAME)



RN 642498-71-3 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-cyclopropyl-4-hydroxy- (CA INDEX NAME)



RN 642498-72-4 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-chloro-5-fluorophenyl)-4-hydroxy-4-(1-naphthalenyl)- (CA INDEX NAME)



RN 642498-73-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-(2,6-dichloro-4-pyridinyl)-4-hydroxy- (CA INDEX NAME)



RN 642498-75-7 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-hydroxy-4-(5-methyl-2-pyridinyl)- (CA INDEX NAME)



RN 642498-76-8 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-hydroxy-4-(6-methoxy-2-pyridinyl)- (CA INDEX NAME)



RN 642498-77-9 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-(ethoxymethyl)-4-hydroxy- (CA INDEX NAME)



RN 642498-78-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(butoxymethyl)-N-(3,5-dichlorophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642498-79-1 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-hydroxy-4-[(phenylmethoxy)methyl]- (CA INDEX NAME)



RN 642498-80-4 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-hydroxy-4-[(1-methylethoxy)methyl]- (CA INDEX NAME)



RN 642498-81-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-pentyl-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642498-82-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-hexyl-4-hydroxy-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642498-83-7 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-dichlorophenyl)-4-hexyl-4-hydroxy- (CA INDEX NAME)



RN 642498-84-8 CAPLUS

CN 1-Piperidinecarboxamide, N-(3,5-dichloro-4-pyridinyl)-4-hexyl-4-hydroxy- (CA INDEX NAME)



RN 642498-85-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-(3-phenoxyphenyl)-4-propyl- (CA INDEX NAME)



RN 642498-86-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-(3-nitrophenyl)- (CA INDEX NAME)



RN 642498-87-1 CAPLUS
CN Benzoic acid, 3-[[[4-(4-bromophenyl)-4-hydroxy-1-piperidinyl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 642498-88-2 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-benzoylphenyl)-4-butyl-4-hydroxy- (CA INDEX NAME)



RN 642498-89-3 CAPLUS
CN 1-Piperidinecarboxamide, N-(3-benzoylphenyl)-4-(4-bromophenyl)-4-hydroxy- (CA INDEX NAME)



RN 642498-90-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-(phenoxymethyl)phenyl]- (CA INDEX NAME)



RN 642498-91-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-phenyl-N-[3-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 642498-92-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-(phenylmethoxy)phenyl]- (CA INDEX NAME)



RN 642498-93-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[(phenylsulfonyl)amino]phenyl]- (CA INDEX NAME)



RN 642498-94-0 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(5-methyl-2-pyridinyl)-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642498-95-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(2-naphthalenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642498-96-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(1-methylpropyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642498-97-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-4-(1-methylbutyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 642499-00-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-butyl-4-hydroxy-N-(3-phenoxyphenyl)- (CA INDEX NAME)



RN 642592-56-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-butyl-4-hydroxy-N-[3-(phenoxymethyl)phenyl]- (CA INDEX NAME)



RN 642592-62-9 CAPLUS
CN 1-Piperidinecarboxamide, N-(3,5-difluorophenyl)-4-(1-ethylpropyl)-4-hydroxy- (CA INDEX NAME)



RN 642592-73-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-butyl-4-hydroxy-N-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 642592-79-8 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-N-(3-ethenylphenyl)-4-hydroxy- (CA INDEX NAME)



RN 642592-86-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-4-hydroxy-4-(1-propylbutyl)- (CA INDEX NAME)



RN 642592-92-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-bromophenyl)-4-hydroxy-N-[3-[[4-(trifluoromethoxy)benzoyl]amino]phenyl]- (CA INDEX NAME)



RN 642592-99-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-cyclopentyl-4-hydroxy-N-(3-methoxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	138.36	909.30

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL

	ENTRY	SESSION
CA SUBSCRIBER PRICE	-19.68	-24.60

STN INTERNATIONAL LOGOFF AT 13:10:27 ON 20 AUG 2009